{"content":"<li class=\"n-box-item date-title\" data-end=\"1547528399\" data-start=\"1547442000\" data-txt=\"Monday, December 23, 2019\">Monday, January 14, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3422934\" data-ts=\"1547509234\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMMU\" target=\"_blank\">IMMU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422934-immunomedics-says-shutdown-wont-slow-cancer-drug-decision\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Immunomedics says shutdown won&#39;t slow cancer drug decision</a></h4><ul>   <li>Immunomedics (NASDAQ:<a href='https://seekingalpha.com/symbol/IMMU' title='Immunomedics, Inc.'>IMMU</a>) says it's progressing with the FDA and doesn't expect a delayed decision on its cancer drug around the government shutdown, Bloomberg reports.</li>    <li>The company's treatment -- sacituzumab govitecan -- has a PDUFA date set this Friday, and would mark Immunomedics' first product on the market.</li>    <li>Shares are <font color=\"green\">up 3.4%</font> on relatively heavy after-hours trading.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3422934\" data-linked=\"Immunomedics says shutdown won&#39;t slow cancer drug decision\" data-tweet=\"$IMMU - Immunomedics says shutdown won&#39;t slow cancer drug decision https://seekingalpha.com/news/3422934-immunomedics-says-shutdown-wont-slow-cancer-drug-decision?source=tweet\" data-url=\"https://seekingalpha.com/news/3422934-immunomedics-says-shutdown-wont-slow-cancer-drug-decision\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:40 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422932\" data-ts=\"1547508595\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JCP\" target=\"_blank\">JCP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422932-jcpenney-sets-leadership-plans-says-cfo-search-is-well-under-way\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JCPenney sets leadership plans, says CFO search is &#39;well under way&#39;</a></h4><ul>   <li>Discussing a series of <a href=\"https://seekingalpha.com/pr/17379574-jcpenney-announces-executive-leadership-changes\" target=\"_blank\">leadership changes</a>, JCPenney (NYSE:<a href='https://seekingalpha.com/symbol/JCP' title='J.C. Penney Company Inc.'>JCP</a>) notes searches are \"well under way\" for a new chief financial officer and chief merchant officer among other key positions it's filling.</li>    <li>The retailer plans a \"cross-functional executive team that merges the talents and perspectives of new and existing industry leaders to focus on the needs of the value-based consumer and position the company for growth.\"</li>    <li>Mike Robbins will be made executive VP and chief stores and supply chain officer, effective Jan. 21. He's currently executive VP of private brands and supply chain.</li>    <li>Truett Horne of McKinsey &amp; Co. will join as chief transformation officer, reported directly to CEO Jill Soltau.</li>    <li>Meanwhile, it's looking for the CFO (a spot for which it has \"many compelling candidates\"); chief merchant (to lead merchandising efforts across categories); a chief customer officer (to grow traffic, engagement and retention); a senior VP of Planning and Allocation (to lead goal-setting for sales, inventory and replenishment); and a principal accounting officer (CAO and Controller Andrew Drexler is leaving the company March 31).</li>    <li>Shares <font color=\"red\">fell 1.5%</font> during the regular session and are <font color=\"green\">up 1.5%</font> after hours.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3422932\" data-linked=\"JCPenney sets leadership plans, says CFO search is &#39;well under way&#39;\" data-tweet=\"$JCP - JCPenney sets leadership plans, says CFO search is &#39;well under way&#39; https://seekingalpha.com/news/3422932-jcpenney-sets-leadership-plans-says-cfo-search-is-well-under-way?source=tweet\" data-url=\"https://seekingalpha.com/news/3422932-jcpenney-sets-leadership-plans-says-cfo-search-is-well-under-way\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>44&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422930\" data-ts=\"1547506929\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EXEL\" target=\"_blank\">EXEL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422930-exelixisplus-4-after-fda-approves-liver-cancer-drug\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Exelixis +4% after FDA approves liver cancer drug</a></h4><ul><li>Exelixis (NASDAQ:<a href='https://seekingalpha.com/symbol/EXEL' title='Exelixis, Inc.'>EXEL</a>) <font color=\"green\">+3.9%</font> after-hours following news that the U.S. Food and Drug Administration <a href=\"https://seekingalpha.com/pr/17379684-exelixis-announces-u-s-fda-approval-cabometyx-cabozantinib-tablets-previously-treated\" target=\"_blank\">approved</a> its Cabometyx tablets for patients with hepatocellular carcinoma - the most common form of liver cancer - who previously were treated with another drug.</li><li>EXEL says the FDA\u2019s approval was based on results from a Phase 3 pivotal trial in which Cabometyx demonstrated a statistically       significant and clinically meaningful improvement in overall survival       vs. placebo.</li><li>Last November, EXEL partner Ipsen       received approval from the European Commission for Cabometyx tablets as       a monotherapy for HCC in adults who previously were treated with       sorafenib.</li></ul><div class=\"tiny-share-widget\" data-id=\"3422930\" data-linked=\"Exelixis +4% after FDA approves liver cancer drug\" data-tweet=\"$EXEL - Exelixis +4% after FDA approves liver cancer drug https://seekingalpha.com/news/3422930-exelixisplus-4-after-fda-approves-liver-cancer-drug?source=tweet\" data-url=\"https://seekingalpha.com/news/3422930-exelixisplus-4-after-fda-approves-liver-cancer-drug\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422929\" data-ts=\"1547506875\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TMUS\" target=\"_blank\">TMUS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422929-t-mobile-confirms-5g-network-is-up-awaiting-compatible-phones\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">T-Mobile confirms its 5G network is up, awaiting compatible phones</a></h4><ul>   <li>T-Mobile (NASDAQ:<a href='https://seekingalpha.com/symbol/TMUS' title='T-Mobile US, Inc.'>TMUS</a>) has quietly confirmed that it has an <a href=\"https://www.lightreading.com/mobile/5g/t-mobile-quietly-confirms-5g-network-in-30-cities/d/d-id/748791?_mc=RSS_LR_EDT\" target=\"_blank\">active 5G network in 30 cities</a>, Light Reading reports, after questioning the carrier about its pledge to do so by the end of 2018.</li>    <li>But the news is quiet because the company says it won't offer commercial services on the network until 5G smartphones are available -- likely the beginning of next year.</li>    <li>Without more details, it's hard to know whether the networks are robust or only a few sites as proof of concept, Mike Dano notes.</li>    <li>But its timeline is closely enough aligned with efforts from key rivals AT&amp;T and Verizon, with particular service launch dates still vague.</li>    <li>T-Mobile is the only major carrier planning to launch its 5G services on 600 MHz spectrum, ideal for long ranges but not optimized for data speed like the 28 GHz and 39 GHz frequencies (which will also be part of T-Mobile's approach).</li>    <li>Shares <font color=\"red\">fell 1.6%</font> during the regular session and are <font color=\"green\">up 1.5%</font> after hours.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3422929\" data-linked=\"T-Mobile confirms its 5G network is up, awaiting compatible phones\" data-tweet=\"$TMUS - T-Mobile confirms its 5G network is up, awaiting compatible phones https://seekingalpha.com/news/3422929-t-mobile-confirms-5g-network-is-up-awaiting-compatible-phones?source=tweet\" data-url=\"https://seekingalpha.com/news/3422929-t-mobile-confirms-5g-network-is-up-awaiting-compatible-phones\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422923\" data-ts=\"1547505440\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BGFV\" target=\"_blank\">BGFV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422923-after-hours-movers-and-shakers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After hours movers and shakers</a></h4><ul><li><strong>Gainers: </strong><a href='https://seekingalpha.com/symbol/BGFV' title='Big 5 Sporting Goods Corporation'>BGFV</a> <font color=\"green\">+10.9%</font>. <a href='https://seekingalpha.com/symbol/PLAY' title='Dave & Buster&#39;s Entertainment, Inc.'>PLAY</a> <font color=\"green\">+6.1%</font>. <a href='https://seekingalpha.com/symbol/FTNW' title='FTE Networks, Inc.'>FTNW</a> <font color=\"green\">+5.2%</font>. <a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca Group plc'>AZN</a> <font color=\"green\">+2.0%</font>. <a href='https://seekingalpha.com/symbol/FTR' title='Frontier Communications Corporation'>FTR</a> <font color=\"green\">+1.9%</font>.</li><li><strong>Losers: </strong><a href='https://seekingalpha.com/symbol/ALNY' title='Alnylam Pharmaceuticals, Inc.'>ALNY</a> <font color=\"red\">-3.5%</font>. <a href='https://seekingalpha.com/symbol/ARR' title='ARMOUR Residential REIT, Inc.'>ARR</a> <font color=\"red\">-2.6%</font>. <a href='https://seekingalpha.com/symbol/VIV' title='Telefonica Brasil, S.A'>VIV</a> <font color=\"red\">-2.1%</font>. <a href='https://seekingalpha.com/symbol/FIT' title='Fitbit, Inc.'>FIT</a> <font color=\"red\">-1.4%</font>. <a href='https://seekingalpha.com/symbol/PFPT' title='Proofpoint, Inc.'>PFPT</a> <font color=\"red\">-0.9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3422923\" data-linked=\"After hours movers and shakers\" data-tweet=\"$BGFV $BGFV $PLAY - After hours movers and shakers https://seekingalpha.com/news/3422923-after-hours-movers-and-shakers?source=tweet\" data-url=\"https://seekingalpha.com/news/3422923-after-hours-movers-and-shakers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422921\" data-ts=\"1547504557\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGI\" target=\"_blank\">AGI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422921-alamos-gold-posts-record-gold-production-for-2018-up-18-y-y\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alamos Gold posts record gold production for 2018, up 18% Y/Y</a></h4><ul><li>Alamos Gold (NYSE:<a href='https://seekingalpha.com/symbol/AGI' title='Alamos Gold Inc'>AGI</a>) <font color=\"green\">+2.1%</font> after-hours on news it <a href=\"https://seekingalpha.com/pr/17379636-alamos-reports-fourth-quarter-2018-production-provides-2019-outlook\" target=\"_blank\">produced a record 505K oz. of gold</a> in 2018, an 18% Y/Y increase, driven by strong performances from Mulatos and Island Gold.</li><li>Q4 production totaled 125.6K oz. of gold, up 4.4% Y/Y, reflecting a stronger performance from Young-Davidson and record production from Island Gold; Q4 sales were a record 131,164  oz. of gold at an average realized price of $1,244/oz. for $163M in revenues.</li><li>For 2019, AGI guides for production of 480K-520K oz. of gold, consistent with 2018 production, at all-in sustaining cost guidance of $920-$960/oz., down 5% from revised 2018 guidance of $990/oz.</li><li>AGI forecasts annual gold production of ~500K oz./year in 2019 and 2020, increasing to 600K-plus oz. in 2021, reflecting a full year of production from Kirazli.</li></ul><div class=\"tiny-share-widget\" data-id=\"3422921\" data-linked=\"Alamos Gold posts record gold production for 2018, up 18% Y/Y\" data-tweet=\"$AGI - Alamos Gold posts record gold production for 2018, up 18% Y/Y https://seekingalpha.com/news/3422921-alamos-gold-posts-record-gold-production-for-2018-up-18-y-y?source=tweet\" data-url=\"https://seekingalpha.com/news/3422921-alamos-gold-posts-record-gold-production-for-2018-up-18-y-y\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422908\" data-ts=\"1547502760\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STML\" target=\"_blank\">STML</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422908-stemline-readies-6_6m-share-stock-offering-shares-down-4-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stemline readies 6.6M-share stock offering; shares down 4% after hours</a></h4><ul><li>Stemline Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/STML' title='Stemline Therapeutics'>STML</a>) is down <font color=\"red\">4%</font> after hours following its <a href=\"https://seekingalpha.com/pr/17379611-stemline-therapeutics-announces-proposed-public-offering-common-stock\" target=\"_blank\">announced </a>6.6M-share stock offering. Price and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3422908\" data-linked=\"Stemline readies 6.6M-share stock offering; shares down 4% after hours\" data-tweet=\"$STML - Stemline readies 6.6M-share stock offering; shares down 4% after hours https://seekingalpha.com/news/3422908-stemline-readies-6_6m-share-stock-offering-shares-down-4-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3422908-stemline-readies-6_6m-share-stock-offering-shares-down-4-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:52 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422897\" data-ts=\"1547501695\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARR\" target=\"_blank\">ARR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422897-armour-residentialminus-2_1-after-5m-share-offering-launches\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ARMOUR Residential -2.1% after 5M-share offering launches</a></h4><ul><li>ARMOUR Residential REIT (NYSE:<a href='https://seekingalpha.com/symbol/ARR' title='ARMOUR Residential REIT, Inc.'>ARR</a>) <font color=\"red\">sinks 2.1%</font> in after-hours trading after announcing a <a href=\"https://seekingalpha.com/pr/17379569-armour-residential-reit-inc-announces-public-offering-5000-000-shares-common-stock\" target=\"_blank\">5M-share common stock offering</a>.</li><li>Greenshoe option of up to 750K additional shares.</li><li>Intends to use proceeds to acquire additional target assets as market conditions warrant and for general corporate purposes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3422897\" data-linked=\"ARMOUR Residential -2.1% after 5M-share offering launches\" data-tweet=\"$ARR - ARMOUR Residential -2.1% after 5M-share offering launches https://seekingalpha.com/news/3422897-armour-residentialminus-2_1-after-5m-share-offering-launches?source=tweet\" data-url=\"https://seekingalpha.com/news/3422897-armour-residentialminus-2_1-after-5m-share-offering-launches\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422896\" data-ts=\"1547501644\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLAY\" target=\"_blank\">PLAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422896-dave-busters-rallies-after-strong-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dave &amp; Buster&#39;s rallies after strong guidance</a></h4><ul><li>Dave &amp; Buster's Entertainment (NASDAQ:<a href='https://seekingalpha.com/symbol/PLAY' title='Dave & Buster&#39;s Entertainment, Inc.'>PLAY</a>) provides a guidance update. The company says it expects to report that FQ4 comparable store sales increased 1.8% to 2.5%. For the full year, revenue is anticipated to land in a range of $1.259B to $1.263B. Net income for the full year is seen coming in at $112M to $114M and EBITDA of $276M to $278M is anticipated.</li>  <li>\"Opening new stores with outstanding returns remains a key priority and we are maintaining our plan to open 15 to 16 new stores in fiscal 2019,\" says D&amp;B's CEO Brian Jenkins.</li>  <li>PLAY  <font color=\"green\">+2.6%</font> AH.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17379573-dave-and-buster-s-updates-fiscal-2018-financial-outlook\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3422896\" data-linked=\"Dave &amp; Buster&#39;s rallies after strong guidance\" data-tweet=\"$PLAY - Dave &amp; Buster&#39;s rallies after strong guidance https://seekingalpha.com/news/3422896-dave-busters-rallies-after-strong-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3422896-dave-busters-rallies-after-strong-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:34 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422892\" data-ts=\"1547501345\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EVBG\" target=\"_blank\">EVBG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422892-everbridge-readies-stock-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Everbridge readies stock offering</a></h4><ul><li>Everbridge (NASDAQ:<a href='https://seekingalpha.com/symbol/EVBG' title='Everbridge'>EVBG</a>) <a href=\"https://seekingalpha.com/pr/17379575-everbridge-announces-proposed-public-offering-common-stock\" target=\"_blank\">launches </a>a $125M public offering of common stock. Price, volume and terms have yet to be announced.</li><li>Shares are down a fraction after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3422892\" data-linked=\"Everbridge readies stock offering\" data-tweet=\"$EVBG - Everbridge readies stock offering https://seekingalpha.com/news/3422892-everbridge-readies-stock-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3422892-everbridge-readies-stock-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:29 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422889\" data-ts=\"1547501241\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BGNE\" target=\"_blank\">BGNE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422889-beigenes-zanubrutinib-breakthrough-therapy-for-aggressive-type-of-nhl\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BeiGene&#39;s zanubrutinib a Breakthrough Therapy for aggressive type of NHL</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/17379561-beigene-receives-u-s-fda-breakthrough-therapy-designation-zanubrutinib-mantle-cell-lymphoma\" target=\"_blank\">designates</a> BeiGene's (NASDAQ:<a href='https://seekingalpha.com/symbol/BGNE' title='BeiGene'>BGNE</a>) BTK inhibitor zanubrutinib a Breakthrough Therapy for the treatment of adult patients with mantle cell lymphoma &#40;MCL&#41; who have received at least one prior line of therapy.</li><li>MCL, an aggressive form of non-Hodgkin lymphoma &#40;NHL&#41;, represents ~6% of new NHL cases.</li><li>Breakthrough Therapy status provides for more intensive guidance from the FDA on development, the involvement of more senior agency personnel and a rolling review of the marketing application.</li><li>Shares are up <font color=\"green\">2%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3422889\" data-linked=\"BeiGene&#39;s zanubrutinib a Breakthrough Therapy for aggressive type of NHL\" data-tweet=\"$BGNE - BeiGene&#39;s zanubrutinib a Breakthrough Therapy for aggressive type of NHL https://seekingalpha.com/news/3422889-beigenes-zanubrutinib-breakthrough-therapy-for-aggressive-type-of-nhl?source=tweet\" data-url=\"https://seekingalpha.com/news/3422889-beigenes-zanubrutinib-breakthrough-therapy-for-aggressive-type-of-nhl\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:27 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422880\" data-ts=\"1547500646\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XLRN\" target=\"_blank\">XLRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422880-acceleron-initiates-200m-stock-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Acceleron initiates $200M stock offering</a></h4><ul><li>Acceleron Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/XLRN' title='Acceleron Pharma Inc.'>XLRN</a>) <a href=\"https://seekingalpha.com/pr/17379513-acceleron-announces-proposed-public-offering-common-stock\" target=\"_blank\">launches </a>a $200M public offering of common stock. Price, volume and terms have yet to be announced.</li><li>Shares are up <font color=\"green\">1%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3422880\" data-linked=\"Acceleron initiates $200M stock offering\" data-tweet=\"$XLRN - Acceleron initiates $200M stock offering https://seekingalpha.com/news/3422880-acceleron-initiates-200m-stock-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3422880-acceleron-initiates-200m-stock-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422877\" data-ts=\"1547500526\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALNY\" target=\"_blank\">ALNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422877-alnylam-launches-5m-share-stock-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alnylam launches 5M-share stock offering</a></h4><ul><li>Alnylam Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ALNY' title='Alnylam Pharmaceuticals, Inc.'>ALNY</a>) <a href=\"https://seekingalpha.com/pr/17379514-alnylam-pharmaceuticals-announces-proposed-public-offering-common-stock\" target=\"_blank\">commences </a>a public offering of 5M shares of common stock. Price and terms have yet to be announced.</li><li>Shares are up <font color=\"green\">2%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3422877\" data-linked=\"Alnylam launches 5M-share stock offering\" data-tweet=\"$ALNY - Alnylam launches 5M-share stock offering https://seekingalpha.com/news/3422877-alnylam-launches-5m-share-stock-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3422877-alnylam-launches-5m-share-stock-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:15 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422870\" data-ts=\"1547500109\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BPTH\" target=\"_blank\">BPTH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422870-bio-path-readies-stock-offering-shares-down-5-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bio-Path readies stock offering; shares down 5% after hours</a></h4><ul><li>Bio-Path Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/BPTH' title='Bio-Path Holdings, Inc.'>BPTH</a>) is down <font color=\"red\">5%</font> after hours in response to its announced <a href=\"https://seekingalpha.com/pr/17379502-bio-path-holdings-inc-announces-proposed-public-offering-common-stock\" target=\"_blank\">stock offering</a>. Price, volume and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3422870\" data-linked=\"Bio-Path readies stock offering; shares down 5% after hours\" data-tweet=\"$BPTH - Bio-Path readies stock offering; shares down 5% after hours https://seekingalpha.com/news/3422870-bio-path-readies-stock-offering-shares-down-5-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3422870-bio-path-readies-stock-offering-shares-down-5-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:08 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422864\" data-ts=\"1547499498\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSLA\" target=\"_blank\">TSLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422864-tesla-in-reverse-amid-detroit-auto-show-buzz\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tesla in reverse amid Detroit Auto Show buzz</a></h4><ul><li>Shares of Tesla (NASDAQ:<a href='https://seekingalpha.com/symbol/TSLA' title='Tesla, Inc.'>TSLA</a>) are <font color=\"red\">down 3.71%</font> in a move some traders are attributing to the news coming out of the Detroit Auto Show.</li><li>Yesterday, Ford (<a href='https://seekingalpha.com/symbol/F' title='Ford Motor Company'>F</a> <font color='green'>+2%</font>) Chairman Bill Ford <a href=\"https://www.cnbc.com/2019/01/14/tesla-under-pressure-as-ford-nissan-and-gm-roll-out-new-competition.html\" target=\"_blank\">outlined</a> the automaker's $11B investment in electric vehicles by 2022 with plans to have 40 hybrid and fully electric vehicles in its model lineup. Tomorrow is also the big announcement on the Ford alliance with Volkswagen that is sure to include electrification and mobility collaboration.</li><li>There is also continued buzz in the Motor City over the all-electric Cadillac coming from General Motors (<a href='https://seekingalpha.com/symbol/GM' title='General Motors Company'>GM</a> <font color='green'>+1.4%</font>), as well as talk on Nissan's (<a href='https://seekingalpha.com/symbol/NSANY' title='Nissan Motor Co., Ltd. ADR'>OTCPK:NSANY</a>) expanding EV plans for the Infiniti brand in 2021.</li></ul><div class=\"tiny-share-widget\" data-id=\"3422864\" data-linked=\"Tesla in reverse amid Detroit Auto Show buzz\" data-tweet=\"$TSLA $TSLA $F - Tesla in reverse amid Detroit Auto Show buzz https://seekingalpha.com/news/3422864-tesla-in-reverse-amid-detroit-auto-show-buzz?source=tweet\" data-url=\"https://seekingalpha.com/news/3422864-tesla-in-reverse-amid-detroit-auto-show-buzz\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>584&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422863\" data-ts=\"1547499360\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BABA\" target=\"_blank\">BABA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422863-alibaba-trades-down-president-discusses-slowing-chinese-economy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alibaba trades down as president discusses slowing Chinese economy</a></h4><ul>   <li>Alibaba (NYSE:<a href='https://seekingalpha.com/symbol/BABA' title='Alibaba Group Holding Limited'>BABA</a>) is dipping anew, now <font color=\"red\">down 1.7%</font>, after some cautious optimism from its president included acknowledgment that China's <a href=\"https://www.wsj.com/articles/alibaba-confident-in-china-sales-despite-troubling-headwinds-11547497720?tesla=y&amp;mod=article_inline\" target=\"_blank\">consumer market continues to decelerate</a>.</li>    <li>\u201cChina has slowed down,\u201d J. Michael Evans says at the National Retail Federation show. \u201cAs a $13 trillion economy, it would be quite unusual if it could continue to grow at 7% or 8%.\u201d</li>    <li>But he still expects China to become the world's largest economy over the next 10 years, led by consumption as a percentage of GDP.</li>    <li>It's a market that \"requires patience,\" Evans says. \"But if you think about where the country is going in the long-term\u2026The future I think looks very good, notwithstanding some troubling headwinds.\u201d</li> </ul><div class=\"tiny-share-widget\" data-id=\"3422863\" data-linked=\"Alibaba trades down as president discusses slowing Chinese economy\" data-tweet=\"$BABA - Alibaba trades down as president discusses slowing Chinese economy https://seekingalpha.com/news/3422863-alibaba-trades-down-president-discusses-slowing-chinese-economy?source=tweet\" data-url=\"https://seekingalpha.com/news/3422863-alibaba-trades-down-president-discusses-slowing-chinese-economy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422862\" data-ts=\"1547499245\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XPO\" target=\"_blank\">XPO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422862-xpo-logistics-cut-keybanc-on-bbfm-competition-european-exposure\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">XPO Logistics cut at KeyBanc on BBFM competition, European exposure</a></h4><ul><li>XPO Logistics (<a href='https://seekingalpha.com/symbol/XPO' title='XPO Logistics, Inc'>XPO</a> <font color='red'>-4.5%</font>) slumps after KeyBanc <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/19/01/12977731/headwinds-competition-for-xpo-logistics-send-keybanc-to\" target=\"_blank\">downgrades</a> shares to Sector Weight from Overweight, citing the increasingly competitive big and bulky final mile market along with macroeconomic weakness in Europe, where the company has high exposure.</li><li>XPO, with its first-mover advantage, has a 7% share of the BBFM market, but competition from well-established and well-capitalized firms could slow its growth from to the mid-to-high teens to low-double digits, says KeyBanc's Todd Fowler.</li><li>The firm thinks the hiring of a CFO with public company exposure and an acquisition track record could be a catalyst, but \"final mile has been viewed as a key differentiator, with increased competition a potential, incremental negative, while ongoing European headwinds imply higher growth in remaining segments to achieve EBITDA targets.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3422862\" data-linked=\"XPO Logistics cut at KeyBanc on BBFM competition, European exposure\" data-tweet=\"$XPO - XPO Logistics cut at KeyBanc on BBFM competition, European exposure https://seekingalpha.com/news/3422862-xpo-logistics-cut-keybanc-on-bbfm-competition-european-exposure?source=tweet\" data-url=\"https://seekingalpha.com/news/3422862-xpo-logistics-cut-keybanc-on-bbfm-competition-european-exposure\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:54 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422861\" data-ts=\"1547499224\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVS\" target=\"_blank\">NVS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422861-novartis-in-crosshairs-of-dutch-health-minister-over-lutathera-price\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Novartis in crosshairs of Dutch health minister over Lutathera price</a></h4><ul><li>Dutch Health Minister Bruno Bruins is <a href=\"https://www.fiercepharma.com/pharma/novartis-accused-gaming-ema-orphan-program-to-price-lutathera-price-sky-high\" target=\"_blank\">accusing </a>Novartis (<a href='https://seekingalpha.com/symbol/NVS' title='Novartis AG'>NVS</a> <font color='red'>-1.1%</font>) of \"gaming\" Orphan Drug status to hike the price of Lutathera (lutetium I77 dotatate), a radiotherapy it acquired in its $2.9B takeout of Advanced Accelerator Applications a year ago. He say the Orphan Drug program was designed to stimulate the development of new medicines, not registering a relatively old experimental therapy. He plans to raise the issue with European authorities.</li><li>According to DutchNews, a full course of treatment (four infusions) costs \u20ac90,000. The company counters that hospitals pay a fraction of that, \u20ac16,000 (\u20ac4,000 per infusion), for house-made versions, adding \u201cthe price of Lutathera was carefully considered and based on the  benefit the treatment provides to patients, healthcare systems and  society at large. It is priced comparably to other existing therapies  approved for this patient population.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3422861\" data-linked=\"Novartis in crosshairs of Dutch health minister over Lutathera price\" data-tweet=\"$NVS - Novartis in crosshairs of Dutch health minister over Lutathera price https://seekingalpha.com/news/3422861-novartis-in-crosshairs-of-dutch-health-minister-over-lutathera-price?source=tweet\" data-url=\"https://seekingalpha.com/news/3422861-novartis-in-crosshairs-of-dutch-health-minister-over-lutathera-price\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422856\" data-ts=\"1547497277\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NOC\" target=\"_blank\">NOC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422856-northrop-grumman-upgraded-credit-suisse-after-2018-correction\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Northrop Grumman upgraded at Credit Suisse after 2018 correction</a></h4><ul><li>Northrop Grumman (<a href='https://seekingalpha.com/symbol/NOC' title='Northrop Grumman Corporation'>NOC</a> <font color='green'>+2.4%</font>) is higher after Credit Suisse <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/19/01/12979864/credit-suisse-expects-northrop-grumman-to-outperform\" target=\"_blank\">upgrades</a> shares to Outperform from Neutral with a $311 price target, citing valuation after the stock tumbled 21% in 2018.</li><li>\"With 2018\u2019s market correction, NOC now has one of the most well supported valuations among the defense primes,\" writes Credit Suisse analyst Robert Spingarn.</li><li>NOC's cutting-edge tech focus is more in line with the direction the U.S. military is moving than it has been in the past, Spingarn says, citing the company\u2019s Common Infrared Countermeasures program as an example of a relatively small but significant high tech product expected to enjoy a revenue ramp over the next several years.</li><li>Among other projects that likely will lead to strong revenue growth in coming years are the F-35 aircraft, on which NOC is a key supplier, and the Air Force\u2019s B-21 Raider stealth bomber, which Spingarn says is one of NOC\u2019s \u201cmost compelling longer-term growth opportunities.\u201d</li></ul><div class=\"tiny-share-widget\" data-id=\"3422856\" data-linked=\"Northrop Grumman upgraded at Credit Suisse after 2018 correction\" data-tweet=\"$NOC - Northrop Grumman upgraded at Credit Suisse after 2018 correction https://seekingalpha.com/news/3422856-northrop-grumman-upgraded-credit-suisse-after-2018-correction?source=tweet\" data-url=\"https://seekingalpha.com/news/3422856-northrop-grumman-upgraded-credit-suisse-after-2018-correction\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:21 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422855\" data-ts=\"1547497192\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BMY\" target=\"_blank\">BMY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422855-congressmen-urge-doj-to-scrutinize-bristol-myers-squibb-celgene-tie-up\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Congressmen urge DOJ to scrutinize Bristol-Myers Squibb - Celgene tie-up</a></h4><ul><li>U.S. Representatives Peter Welch (D-VT At large) and Francis Rooney (R-FL 19th District) have <a href=\"https://welch.house.gov/sites/welch.house.gov/files/Letter%20to%20FTC%20and%20DOJ%20on%20BMS%20Celgene%20Merger.pdf\" target=\"_blank\">sent a letter</a> to the Federal Trade Commission and the Department of Justice urging a \"careful examination\" of Bristol-Myers Squibb's (<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a> <font color='green'>+0.7%</font>) $74B takeout of Celgene (<a href='https://seekingalpha.com/symbol/CELG' title='Celgene Corporation'>CELG</a> <font color='green'>+0.1%</font>).</li><li>The lawmakers cite the potential negative impact on competition and drug prices as the reasons for their suggested scrutiny.</li></ul><div class=\"tiny-share-widget\" data-id=\"3422855\" data-linked=\"Congressmen urge DOJ to scrutinize Bristol-Myers Squibb - Celgene tie-up\" data-tweet=\"$BMY $BMY $CELG - Congressmen urge DOJ to scrutinize Bristol-Myers Squibb - Celgene tie-up https://seekingalpha.com/news/3422855-congressmen-urge-doj-to-scrutinize-bristol-myers-squibb-celgene-tie-up?source=tweet\" data-url=\"https://seekingalpha.com/news/3422855-congressmen-urge-doj-to-scrutinize-bristol-myers-squibb-celgene-tie-up\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422843\" data-ts=\"1547496285\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BOXL\" target=\"_blank\">BOXL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422843-microcaps-mostly-among-tech-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Microcaps mostly among tech movers</a></h4><ul><li><strong>Gainers: </strong>Boxlight Corporation (NASDAQ:<a href='https://seekingalpha.com/symbol/BOXL' title='Boxlight'>BOXL</a>) <font color=\"green\">+23%</font>. Identiv (NASDAQ:<a href='https://seekingalpha.com/symbol/INVE' title='Identiv, Inc.'>INVE</a>) <font color=\"green\">+22%</font>. USA Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/USAT' title='USA Technologies, Inc.'>USAT</a>) <font color=\"green\">+21%</font>. Borqs Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/BRQS' title='Borqs Technologies, Inc'>BRQS</a>) <font color=\"green\">+16%</font>. Gridsum Holding (NASDAQ:<a href='https://seekingalpha.com/symbol/GSUM' title='Gridsum Holding'>GSUM</a>) <font color=\"green\">+11%</font>.</li> <li><strong>Losers: </strong>Inpixon (NASDAQ:<a href='https://seekingalpha.com/symbol/INPX' title='Inpixon'>INPX</a>) <font color=\"red\">-26%</font>. Summit Wireless Technologies (<a href='https://seekingalpha.com/symbol/WISA' title='Summit Semiconductor Inc'>WISA</a>) <font color=\"red\">-16%</font>. Internet Gold - Golden Lines (NASDAQ:<a href='https://seekingalpha.com/symbol/IGLD' title='Internet Gold Golden Lines Ltd.'>IGLD</a>) <font color=\"red\">-16%</font>. CooTek (NYSE:<a href='https://seekingalpha.com/symbol/CTK' title='CooTek'>CTK</a>) <font color=\"red\">-16%</font>. Autohome (NYSE:<a href='https://seekingalpha.com/symbol/ATHM' title='Autohome Inc.'>ATHM</a>) <font color=\"red\">-14%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3422843\" data-linked=\"Microcaps mostly among tech movers\" data-tweet=\"$BOXL $BOXL $INVE - Microcaps mostly among tech movers https://seekingalpha.com/news/3422843-microcaps-mostly-among-tech-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3422843-microcaps-mostly-among-tech-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422841\" data-ts=\"1547495989\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHK\" target=\"_blank\">CHK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422841-nat-gas-futures-soar-16-following-new-weather-forecast\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nat gas futures soar 16% following new weather forecast</a></h4><ul><li><a href=\"https://www.cnbc.com/2019/01/14/natural-gas-prices-spike-13-percent-on-forecasts-for-long-severe-cold.html\" target=\"_blank\">Natural gas futures surge</a>, settling <font color=\"green\">+15.9%</font> to $3.591/MMBtu, following weekend weather and new forecasts calling for some rather cold weather through the end of the month.</li><li>The February Henry Hub futures contract hit a session peak at $3.539/MMBtu, its highest level since Dec. 27.</li><li>\"The forecast has turned significantly colder,\" says Jacob Meisel, chief weather analyst at Bespoke Weather Services. \"It\u2019s really  the magnitude of the cold and the confidence in severity longer term  that\u2019s changed over the weekend.\"</li><li>With natural gas inventories still 15% below the five-year  average, Barclays sees room for higher prices even if  weather normalizes during the rest of winter, and forecasts Henry Hub prices to average $3.51/MMBtu in Q1 and $2.92/MMBtu for the full year.</li><li>\"The market had seemingly written off a return to cold weather during  the downturn of the last six weeks or so, and today\u2019s price action is a  good reminder that there\u2019s still a lot of winter left,\" says Barclays' VP for global gas and energy Sam  Phillips.</li><li>Most gas-focused equities show solid gains: <a href='https://seekingalpha.com/symbol/CHK' title='Chesapeake Energy Corporation'>CHK</a> <font color=\"green\">+2.2%</font>, <a href='https://seekingalpha.com/symbol/EQT' title='EQT Corporation'>EQT</a> <font color=\"green\">+2.1%</font>, <a href='https://seekingalpha.com/symbol/COG' title='Cabot Oil & Gas Corporation'>COG</a> <font color=\"green\">+1.5%</font>, <a href='https://seekingalpha.com/symbol/RRC' title='Range Resources Corporation'>RRC</a> <font color=\"green\">+2.4%</font>, <a href='https://seekingalpha.com/symbol/AR' title='Antero Resources Corporation'>AR</a> <font color=\"green\">+2.2%</font>, <a href='https://seekingalpha.com/symbol/GPOR' title='Gulfport Energy Corporation'>GPOR</a> <font color=\"green\">+1%</font>, <a href='https://seekingalpha.com/symbol/SWN' title='Southwestern Energy Co.'>SWN</a> <font color=\"green\">+0.2%</font>.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/UNG' title='The United States Natural Gas ETF, LP'>UNG</a>, <a href='https://seekingalpha.com/symbol/UGAZ' title='VelocityShares 3x Long Natural Gas ETN'>UGAZ</a>, <a href='https://seekingalpha.com/symbol/DGAZ' title='VelocityShares 3x Inverse Natural Gas ETN'>DGAZ</a>, <a href='https://seekingalpha.com/symbol/BOIL' title='ProShares Ultra Bloomberg Natural Gas ETF'>BOIL</a>, <a href='https://seekingalpha.com/symbol/GASL' title='Direxion Daily Natural Gas Related Bull 3x Shares ETF'>GASL</a>, <a href='https://seekingalpha.com/symbol/FCG' title='First Trust Natural Gas ETF'>FCG</a>, <a href='https://seekingalpha.com/symbol/KOLD' title='ProShares UltraShort Bloomberg Natural Gas ETF'>KOLD</a>, <a href='https://seekingalpha.com/symbol/UNL' title='The United States 12 Month Natural Gas ETF, LP'>UNL</a>, <a href='https://seekingalpha.com/symbol/GASX' title='Direxion Daily Natural Gas Related Bear 3X Shares ETF'>GASX</a>, <a href='https://seekingalpha.com/symbol/GAZB' title='iPath Series B Bloomberg Natural Gas Subindex Total Return ETN'>GAZB</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3422841\" data-linked=\"Nat gas futures soar 16% following new weather forecast\" data-tweet=\"$CHK $CHK $EQT - Nat gas futures soar 16% following new weather forecast https://seekingalpha.com/news/3422841-nat-gas-futures-soar-16-following-new-weather-forecast?source=tweet\" data-url=\"https://seekingalpha.com/news/3422841-nat-gas-futures-soar-16-following-new-weather-forecast\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>110&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422838\" data-ts=\"1547495336\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NEM\" target=\"_blank\">NEM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422838-newmont-s-goldcorp-deal-needs-drastic-surgery-to-pay-off-analyst-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Newmont\u2019s Goldcorp deal needs &#39;drastic surgery&#39; to pay off, analyst says</a></h4><ul><li>The <a href=\"https://seekingalpha.com/news/3422587-newmont-mining-goldcorp-combine-10b-stock-deal\" target=\"_blank\">merged company</a> created by combining Newmont Mining (<a href='https://seekingalpha.com/symbol/NEM' title='Newmont Mining Corporation &#40;Holding Company&#41;'>NEM</a> <font color=\"red\">-8.8%</font>) and Goldcorp (<a href='https://seekingalpha.com/symbol/GG' title='Goldcorp Inc.'>GG</a> <font color=\"green\">+8%</font>) will have the world\u2019s largest production and reserve base, and the kind of liquidity and diversified assets required to attract institutional investors, yet NEM \"has some <a href=\"https://finance.yahoo.com/news/newmont-goldcorp-gamble-may-drastic-172148586.html\" target=\"_blank\">difficult times ahead</a>, with drastic surgery needed at Goldcorp,\" says Maison Placements Canada analyst John Ing.</li><li>\"In the short term and medium term, the deal is not good for Newmont,\" Ing tells Bloomberg.</li><li>GG's recent share price weakness \"<a href=\"https://www.barrons.com/articles/why-newmont-minings-deal-for-goldcorp-looks-attractive-51547485589\" target=\"_blank\">underscores the market\u2019s perception</a> of both Goldcorp\u2019s assets and operating conditions,\" writes Morgan Stanley's Piyush Sood. \"With Newmont\u2019s management acquiring operational control, execution concerns at the new assets will slowly lift, but Newmont will have to reassure investors that the assets are indeed NAV accretive and  won\u2019t lead to another negative reset in expectations.\"</li><li>But Scotiabank analysts say the deal is <a href=\"https://www.reuters.com/article/us-goldcorp-m-a-newmont-mining/newmont-takes-top-gold-producer-spot-with-10-billion-goldcorp-buy-idUSKCN1P80UM\" target=\"_blank\">positive for NEM</a>, \"because it establishes it as the world\u2019s leading gold producer with a deal that is accretive on nearly all key metrics.\"</li><li>Barclays analyst Matthew Murphy praises the \"<a href=\"https://www.barrons.com/articles/why-newmont-minings-deal-for-goldcorp-looks-attractive-51547485589\" target=\"_blank\">fairly compelling rationale</a>\" for the deal because GG was trading for just 0.97x his estimate of net asset value before the announcement while NEM fetched ~1.5x NAV.</li><li>\"Long term, Goldcorp investors may be disappointed, even with the 17% premium offered, as the company\u2019s long promised (and long delayed) recovery was supposed to begin this year,\" writes J.P. Morgan's John Bridges, who thinks GG was 65% undervalued vs. NEM\u2019s 15%.</li><li>\"The industry clearly feels that it needs to do something to become more relevant. One way to do that is just to become bigger,\" says RBC's James Bell. \"The question becomes now, will there be a domino effect?\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3422838\" data-linked=\"Newmont\u2019s Goldcorp deal needs &#39;drastic surgery&#39; to pay off, analyst says\" data-tweet=\"$NEM $NEM $GG - Newmont\u2019s Goldcorp deal needs &#39;drastic surgery&#39; to pay off, analyst says https://seekingalpha.com/news/3422838-newmont-s-goldcorp-deal-needs-drastic-surgery-to-pay-off-analyst-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3422838-newmont-s-goldcorp-deal-needs-drastic-surgery-to-pay-off-analyst-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>38&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422828\" data-ts=\"1547492764\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CGC\" target=\"_blank\">CGC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422828-ny-grants-hemp-license-to-canopy-growth-shares-up-11\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NY grants hemp license to Canopy Growth; shares up 11%</a></h4><ul><li>The State of New York has granted a <a href=\"https://seekingalpha.com/pr/17379388-canopy-growth-receives-new-york-state-hemp-licence-will-establish-u-s-based-commercial\" target=\"_blank\">license </a>to Canopy Growth (<a href='https://seekingalpha.com/symbol/CGC' title='Canopy Growth Corporation'>CGC</a> <font color=\"green\">+11.2%</font>) allowing it to process and produce hemp. The company plans to invest $100M - 150M in the state to establish operations capable of producing \"tons of hemp\" annually.</li><li>Related ticers: (<a href='https://seekingalpha.com/symbol/TLRY' title='Tilray, Inc.'>TLRY</a> <font color=\"green\">+6.7%</font>)(<a href='https://seekingalpha.com/symbol/CRON' title='Cronos Group, Inc.'>CRON</a> <font color=\"green\">+2%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3422828\" data-linked=\"NY grants hemp license to Canopy Growth; shares up 11%\" data-tweet=\"$CGC $CGC $TLRY - NY grants hemp license to Canopy Growth; shares up 11% https://seekingalpha.com/news/3422828-ny-grants-hemp-license-to-canopy-growth-shares-up-11?source=tweet\" data-url=\"https://seekingalpha.com/news/3422828-ny-grants-hemp-license-to-canopy-growth-shares-up-11\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>109&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422827\" data-ts=\"1547492527\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VIA\" target=\"_blank\">VIA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422827-viacom-reportedly-eyes-potential-sale-of-majority-stake-in-china-ops\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Viacom reportedly eyes potential sale of majority stake in China ops</a></h4><ul>   <li>Viacom (<a href='https://seekingalpha.com/symbol/VIA' title='Viacom Inc.'>VIA</a> <font color=\"green\">+1.7%</font>, <a href='https://seekingalpha.com/symbol/VIAB' title='Viacom Inc.'>VIAB</a> <font color=\"green\">+2%</font>) is higher today following yesterday's <i>WSJ</i> report that the company is in talks to <a href=\"https://www.wsj.com/articles/viacom-weighs-majority-stake-sale-of-china-operations-11547380803?mod=searchresults&amp;page=1&amp;pos=1\" target=\"_blank\">sell a majority stake</a> in some China operations.</li>    <li>Such a move would follow other major U.S. multinational divestments from China, and reflect troubles trying to scale business there recently.</li>    <li>Viacom could sell control of its channel brands like MTV and Nickelodeon in a move that would mirror a similar Viacom JV with Reliance in india.</li>    <li>Viacom's also reportedly in <a href=\"https://seekingalpha.com/news/3422507-report-viacom-talks-acquire-streaming-service-tubi-tv\" target=\"_blank\">talks to acquire</a> streaming service Tubi TV.</li>    </ul><div class=\"tiny-share-widget\" data-id=\"3422827\" data-linked=\"Viacom reportedly eyes potential sale of majority stake in China ops\" data-tweet=\"$VIA $VIA $VIAB - Viacom reportedly eyes potential sale of majority stake in China ops https://seekingalpha.com/news/3422827-viacom-reportedly-eyes-potential-sale-of-majority-stake-in-china-ops?source=tweet\" data-url=\"https://seekingalpha.com/news/3422827-viacom-reportedly-eyes-potential-sale-of-majority-stake-in-china-ops\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422826\" data-ts=\"1547492457\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PED\" target=\"_blank\">PED</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422826-pedevco-and-midstates-petroleum-among-energy-materials-gainers-camber-energy-and-ion\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PEDEVCO and Midstates Petroleum among Energy/Materials gainers; Camber Energy and ION Geophysical among losers</a></h4><ul><li><b>Gainers: </b>PEDEVCO (NYSEMKT:<a href='https://seekingalpha.com/symbol/PED' title='PEDEVCO Corp.'>PED</a>) <font color=\"green\">+38%</font>. Midstates Petroleum (NYSE:<a href='https://seekingalpha.com/symbol/MPO' title='Midstates Petroleum'>MPO</a>) <font color=\"green\">+14%</font>. Genie Energy (NYSE:<a href='https://seekingalpha.com/symbol/GNE' title='Genie Energy Ltd.'>GNE</a>) <font color=\"green\">+10%</font>. Ferrellgas Partners (NYSE:<a href='https://seekingalpha.com/symbol/FGP' title='Ferrellgas Partners L.P'>FGP</a>) <font color=\"green\">+8%</font>. Rowan Companies (NYSE:<a href='https://seekingalpha.com/symbol/RDC' title='Rowan Companies plc'>RDC</a>) <font color=\"green\">+7%</font>.</li><li><b>Losers: </b>Camber Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/CEI' title='Camber Energy, Inc.'>CEI</a>) <font color=\"red\">-18%</font>. ION Geophysical (NYSE:<a href='https://seekingalpha.com/symbol/IO' title='ION Geophysical Corporation'>IO</a>) <font color=\"red\">-11%</font>. Newmont Mining (NYSE:<a href='https://seekingalpha.com/symbol/NEM' title='Newmont Mining Corporation &#40;Holding Company&#41;'>NEM</a>) <font color=\"red\">-9%</font>. SandRidge Mississippian Trust II (NYSE:<a href='https://seekingalpha.com/symbol/SDR' title='SandRidge Mississippian Trust II'>SDR</a>) <font color=\"red\">-7%</font>. Flotek Industries (NYSE:<a href='https://seekingalpha.com/symbol/FTK' title='Flotek Industries, Inc.'>FTK</a>) <font color=\"red\">-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3422826\" data-linked=\"PEDEVCO and Midstates Petroleum among Energy/Materials gainers; Camber Energy and ION Geophysical among losers\" data-tweet=\"$PED $PED $AMPY - PEDEVCO and Midstates Petroleum among Energy/Materials gainers; Camber Energy and ION Geophysical among losers https://seekingalpha.com/news/3422826-pedevco-and-midstates-petroleum-among-energy-materials-gainers-camber-energy-and-ion?source=tweet\" data-url=\"https://seekingalpha.com/news/3422826-pedevco-and-midstates-petroleum-among-energy-materials-gainers-camber-energy-and-ion\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422808\" data-ts=\"1547488701\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INST\" target=\"_blank\">INST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422808-instructureminus-8_5-still-bullish-raymond-james-downgrades\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Instructure -8.5% as still-bullish Raymond James downgrades</a></h4><ul>   <li>Instructure (NYSE:<a href='https://seekingalpha.com/symbol/INST' title='Instructure'>INST</a>) has <font color=\"red\">slid 8.5%</font> to a three-week low after drawing a downgrade from bull Raymond James.</li>    <li>The firm cut its rating to Outperform, from Strong Buy.</li>    <li>Volume is heavy and nearing its daily average already.</li>    <li>Analyst Brian Peterson is keeping his $45 target, though, which today is implying 21% upside.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3422808\" data-linked=\"Instructure -8.5% as still-bullish Raymond James downgrades\" data-tweet=\"$INST - Instructure -8.5% as still-bullish Raymond James downgrades https://seekingalpha.com/news/3422808-instructureminus-8_5-still-bullish-raymond-james-downgrades?source=tweet\" data-url=\"https://seekingalpha.com/news/3422808-instructureminus-8_5-still-bullish-raymond-james-downgrades\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:58 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422807\" data-ts=\"1547488619\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OXBR\" target=\"_blank\">OXBR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422807-oxbridge-re-holdings-leads-financial-gainers-loop-industries-and-360-finance-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oxbridge Re Holdings leads financial gainers; Loop Industries and 360 Finance among losers</a></h4><ul><li><b>Gainers:</b> Oxbridge Re Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/OXBR' title='Oxbridge Re Holdings Limited'>OXBR</a>) <font color=\"green\">+10%</font>. Innovative Industrial Properties (NYSE:<a href='https://seekingalpha.com/symbol/IIPR' title='Innovative Industrial Properties'>IIPR</a>) <font color=\"green\">+6%</font>. Ocwen Financial (NYSE:<a href='https://seekingalpha.com/symbol/OCN' title='Ocwen Financial Corporation'>OCN</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers:</b> eXp World Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/EXPI' title='eXp World Holdings, Inc.'>EXPI</a>) <font color=\"red\">-9%</font>. Loop Industries (NASDAQ:<a href='https://seekingalpha.com/symbol/LOOP' title='Loop Industries, Inc.'>LOOP</a>) <font color=\"red\">-8%</font>. 360 Finance (NASDAQ:<a href='https://seekingalpha.com/symbol/QFIN' title='360 Finance'>QFIN</a>) <font color=\"red\">-7%</font>. X Financial (NYSE:<a href='https://seekingalpha.com/symbol/XYF' title='X Financial'>XYF</a>) <font color=\"red\">-6%</font>. PPDAI Group (NYSE:<a href='https://seekingalpha.com/symbol/PPDF' title='PPDAI Group Inc.'>PPDF</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3422807\" data-linked=\"Oxbridge Re Holdings leads financial gainers; Loop Industries and 360 Finance among losers\" data-tweet=\"$OXBR $OXBR $IIPR - Oxbridge Re Holdings leads financial gainers; Loop Industries and 360 Finance among losers https://seekingalpha.com/news/3422807-oxbridge-re-holdings-leads-financial-gainers-loop-industries-and-360-finance-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3422807-oxbridge-re-holdings-leads-financial-gainers-loop-industries-and-360-finance-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422806\" data-ts=\"1547488382\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MBOT\" target=\"_blank\">MBOT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422806-vvus-rnn-mbot-pcg-among-midday-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">VVUS, RNN, MBOT &amp; PCG among midday movers</a></h4><ul><li><strong>Gainers: </strong>Microbot Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/MBOT' title='Microbot Medical Inc'>MBOT</a>) <font color=\"green\">+224%</font>. PEDEVCO (NYSEMKT:<a href='https://seekingalpha.com/symbol/PED' title='PEDEVCO Corp.'>PED</a>) <font color=\"green\">+41%</font>. Renmin Tianli Group (NASDAQ:<a href='https://seekingalpha.com/symbol/ABAC-OLD' title='Renmin Tianli Group'>ABAC-OLD</a>) <font color=\"green\">+37%</font>.</li><li>VIVUS (NASDAQ:<a href='https://seekingalpha.com/symbol/VVUS' title='Vivus, Inc.'>VVUS</a>) <font color=\"green\">+23%</font>. USA Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/USAT' title='USA Technologies, Inc.'>USAT</a>) <font color=\"green\">+21%</font>. Gannett (NYSE:<a href='https://seekingalpha.com/symbol/GCI' title='Gannett Co., Inc.'>GCI</a>) <font color=\"green\">+20%</font>. Boxlight Corporation (NASDAQ:<a href='https://seekingalpha.com/symbol/BOXL' title='Boxlight'>BOXL</a>) <font color=\"green\">+21%</font>. Borqs Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/BRQS' title='Borqs Technologies, Inc'>BRQS</a>) <font color=\"green\">+17%</font>. Rexahn Pharmaceuticals (NYSEMKT:<a href='https://seekingalpha.com/symbol/RNN' title='Rexahn Pharmaceuticals Inc'>RNN</a>) <font color=\"green\">+17%</font>. Co-Diagnostics (NASDAQ:<a href='https://seekingalpha.com/symbol/CODX' title='Co-Diagnostics'>CODX</a>) <font color=\"green\">+16%</font>.</li> <li><strong>Losers: </strong>PG&amp;E Corporation (NYSE:<a href='https://seekingalpha.com/symbol/PCG' title='PG&E Corporation'>PCG</a>) <font color=\"red\">-47%</font>. Verona Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/VRNA' title='Verona Pharma plc'>VRNA</a>) <font color=\"red\">-36%</font>. Inpixon (NASDAQ:<a href='https://seekingalpha.com/symbol/INPX' title='Inpixon'>INPX</a>) <font color=\"red\">-22%</font>. Unifi (NYSE:<a href='https://seekingalpha.com/symbol/UFI' title='Unifi Inc'>UFI</a>) <font color=\"red\">-20%</font>. Tailored Brands (NYSE:<a href='https://seekingalpha.com/symbol/TLRD' title='Tailored Brands, Inc'>TLRD</a>) <font color=\"red\">-15%</font>. AXT (NASDAQ:<a href='https://seekingalpha.com/symbol/AXTI' title='AXT Inc'>AXTI</a>) <font color=\"red\">-14%</font>. CooTek (NYSE:<a href='https://seekingalpha.com/symbol/CTK' title='CooTek'>CTK</a>) <font color=\"red\">-14%</font>. ToughBuilt Industries (NASDAQ:<a href='https://seekingalpha.com/symbol/TBLT' title='ToughBuilt Industries, Inc.'>TBLT</a>) <font color=\"red\">-14%</font>. Autohome (NYSE:<a href='https://seekingalpha.com/symbol/ATHM' title='Autohome Inc.'>ATHM</a>) <font color=\"red\">-13%</font>. Stein Mart (NASDAQ:<a href='https://seekingalpha.com/symbol/SMRT' title='Stein Mart, Inc.'>SMRT</a>) <font color=\"red\">-13%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3422806\" data-linked=\"VVUS, RNN, MBOT &amp; PCG among midday movers\" data-tweet=\"$MBOT $MBOT $PED - VVUS, RNN, MBOT &amp; PCG among midday movers https://seekingalpha.com/news/3422806-vvus-rnn-mbot-pcg-among-midday-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3422806-vvus-rnn-mbot-pcg-among-midday-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:53 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422802\" data-ts=\"1547486425\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZAYO\" target=\"_blank\">ZAYO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422802-zayo-briefly-spikes-on-report-of-offer-30-share\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zayo briefly spikes on report of offer at $30/share or more</a></h4><ul>   <li>Shares in Zayo Group (<a href=\"http://seekingalpha.com/symbol/ZAYO\" target=\"_blank\">ZAYO</a> <font color=\"red\">-1.2%</font>) spiked briefly after a report by <a href=\"https://ctfn.news\" target=\"_blank\">CTFN</a> that the company received an offer in excess of $30/share, but quickly retreated.</li>    <li>The stock was <font color=\"green\">up as much as 1.7%</font> immediately following the news this hour, but are already back in the red for the day, sitting at $25.78 vs. that reported $30-plus offer from a private-equity consortium.</li><li>That offer followed an original rejected offer but the bid's been complicated by debt-market volatility, according to the report.</li>    <li>The company's been on a slide in the past half-year, with shares <font color=\"red\">down 33.7%</font> over the past six months. They're still <font color=\"green\">up 7%</font> over the past week.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3422802\" data-linked=\"Zayo briefly spikes on report of offer at $30/share or more\" data-tweet=\"$ZAYO - Zayo briefly spikes on report of offer at $30/share or more https://seekingalpha.com/news/3422802-zayo-briefly-spikes-on-report-of-offer-30-share?source=tweet\" data-url=\"https://seekingalpha.com/news/3422802-zayo-briefly-spikes-on-report-of-offer-30-share\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422801\" data-ts=\"1547485887\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UNH\" target=\"_blank\">UNH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422801-unitedhealth-reports-tomorrow-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UnitedHealth reports tomorrow; shares up 1%</a></h4><ul><li>UnitedHealth Group (<a href='https://seekingalpha.com/symbol/UNH' title='UnitedHealth Group Inc.'>UNH</a> <font color=\"green\">+0.7%</font>) kicks off the healthcare Q4 earnings season tomorrow morning before the open. Consensus view is non-GAAP EPS of $3.21 on revenues of $59.7B.</li><li><strong>2019 guidance</strong> (will be updated in press release): revenues: $243B - 245B; non-GAAP EPS: $14.40 - 14.70.</li></ul><div class=\"tiny-share-widget\" data-id=\"3422801\" data-linked=\"UnitedHealth reports tomorrow; shares up 1%\" data-tweet=\"$UNH - UnitedHealth reports tomorrow; shares up 1% https://seekingalpha.com/news/3422801-unitedhealth-reports-tomorrow-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3422801-unitedhealth-reports-tomorrow-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422798\" data-ts=\"1547485371\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABAC-OLD\" target=\"_blank\">ABAC-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422798-lululemon-athletica-and-new-age-beverages-among-consumer-gainers-pyxus-international-leads\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lululemon Athletica and New Age Beverages among consumer gainers; Pyxus International leads losers</a></h4><ul><li><b>Gainers: </b>Renmin Tianli Group (NASDAQ:<a href='https://seekingalpha.com/symbol/ABAC-OLD' title='Renmin Tianli Group'>ABAC-OLD</a>) <font color=\"green\">+28%</font>. Lululemon Athletica (NASDAQ:<a href='https://seekingalpha.com/symbol/LULU' title='Lululemon Athletica Inc.'>LULU</a>) <font color=\"green\">+9%</font>. YETI Holdings (NYSE:<a href='https://seekingalpha.com/symbol/YETI' title='Yeti Holdings'>YETI</a>) <font color=\"green\">+9%</font>. New Age Beverages (NASDAQ:<a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a>) <font color=\"green\">+9%</font>. China Automotive Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/CAAS' title='China Automotive Systems, Inc.'>CAAS</a>) <font color=\"green\">+7%</font>.</li><li><b>Losers: </b>Pyxus International (NYSE:<a href='https://seekingalpha.com/symbol/PYX' title='Pyxus International, Inc.'>PYX</a>) <font color=\"red\">-9%</font>. At Home Group (NASDAQ:<a href='https://seekingalpha.com/symbol/HOME' title='At Home Group'>HOME</a>) <font color=\"red\">-8%</font>. Cryoport (NASDAQ:<a href='https://seekingalpha.com/symbol/CYRX' title='CryoPort, Inc.'>CYRX</a>) <font color=\"red\">-7%</font>. Tuniu (NASDAQ:<a href='https://seekingalpha.com/symbol/TOUR' title='Tuniu Corporation'>TOUR</a>) <font color=\"red\">-6%</font>. Celsius Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/CELH' title='Celsius Holdings, Inc.'>CELH</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3422798\" data-linked=\"Lululemon Athletica and New Age Beverages among consumer gainers; Pyxus International leads losers\" data-tweet=\"$ABAC-OLD $ABAC-OLD $LULU - Lululemon Athletica and New Age Beverages among consumer gainers; Pyxus International leads losers https://seekingalpha.com/news/3422798-lululemon-athletica-and-new-age-beverages-among-consumer-gainers-pyxus-international-leads?source=tweet\" data-url=\"https://seekingalpha.com/news/3422798-lululemon-athletica-and-new-age-beverages-among-consumer-gainers-pyxus-international-leads\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422797\" data-ts=\"1547485296\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MED\" target=\"_blank\">MED</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422797-medifast-sees-2018-eps-of-4_45-4_50\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Medifast sees 2018 EPS of $4.45 - 4.50</a></h4><ul><li>In its January corporate <a href=\"https://www.sec.gov/Archives/edgar/data/910329/000114420419001523/tv510983_ex99-1.htm\" target=\"_blank\">presentation </a>(slide #33), Medifast (<a href='https://seekingalpha.com/symbol/MED' title='Medifast, Inc.'>MED</a> <font color=\"red\">-0.9%</font>) expects 2018 revenue of $492.5M - 497.5M compared to consensus of $498.0M. EPS forecast is $4.45 - 4.50 versus consensus of $4.52.</li></ul><div class=\"tiny-share-widget\" data-id=\"3422797\" data-linked=\"Medifast sees 2018 EPS of $4.45 - 4.50\" data-tweet=\"$MED - Medifast sees 2018 EPS of $4.45 - 4.50 https://seekingalpha.com/news/3422797-medifast-sees-2018-eps-of-4_45-4_50?source=tweet\" data-url=\"https://seekingalpha.com/news/3422797-medifast-sees-2018-eps-of-4_45-4_50\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422795\" data-ts=\"1547485143\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/C\" target=\"_blank\">C</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422795-citi-perks-up-volatility-moderates\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Citi perks up as volatility moderates</a></h4><ul><li>Citigroup (NYSE:<a href='https://seekingalpha.com/symbol/C' title='Citigroup Inc.'>C</a>)<font color=\"green\"> revives 3.8%</font> after its chief financial officer says the trading environment<a href=\"https://www.bloomberg.com/news/articles/2019-01-14/citi-fixed-income-trading-slumps-21-in-bad-omen-for-wall-street?srnd=premium\" target=\"_blank\"> started to improve</a> this month.</li><li>\"Volatility has somewhat moderated and both equity prices and yields have shown signs of stabilization,\" CFO John Gerspach told reporters on a call.</li><li>The bank reported earlier that FICC revenue sank 39% in Q4 vs. Q3 as market volatility kept investors on the sidelines. Its shares had declined as much as 1.7% soon after the market opened.</li><li>Banks, overall, perked up after an initial decline Monday morning. The Financial Select Sector SPDR ETF (NYSEARCA:<a href='https://seekingalpha.com/symbol/XLF' title='Financial Select Sector SPDR ETF'>XLF</a>) is <font color=\"green\">up about 0.6%</font> at midday.</li><li>Citi's peers are also in the green: Morgan Stanley (<a href='https://seekingalpha.com/symbol/MS' title='Morgan Stanley'>MS</a> <font color=\"green\">+0.8%</font>), Bank of America (<a href='https://seekingalpha.com/symbol/BAC' title='Bank of America Corporation'>BAC</a> <font color=\"green\">+0.8%</font>), JPMorgan (<a href='https://seekingalpha.com/symbol/JPM' title='JPMorgan Chase & Co.'>JPM</a> <font color=\"green\">+0.7%</font>), Goldman Sachs (<a href='https://seekingalpha.com/symbol/GS' title='Goldman Sachs Group Inc.'>GS</a> <font color=\"green\">+0.5%</font>), and Wells Fargo (<a href='https://seekingalpha.com/symbol/WFC' title='Wells Fargo & Co.'>WFC</a> <font color=\"green\">+0.3%</font>).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3422666-citigroup-revenue-misses-ugly-quarter-fixed-income\" target=\"_blank\">Citigroup revenue misses on ugly quarter for fixed income</a> (Jan. 14)</li></ul><div class=\"tiny-share-widget\" data-id=\"3422795\" data-linked=\"Citi perks up as volatility moderates\" data-tweet=\"$C $C $XLF - Citi perks up as volatility moderates https://seekingalpha.com/news/3422795-citi-perks-up-volatility-moderates?source=tweet\" data-url=\"https://seekingalpha.com/news/3422795-citi-perks-up-volatility-moderates\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422794\" data-ts=\"1547485050\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LILAK\" target=\"_blank\">LILAK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422794-reuters-liberty-latin-america-bidding-for-millicom-shares-jump\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Reuters: Liberty Latin America bidding for Millicom; shares jump</a></h4><ul>   <li>Liberty Latin America (NASDAQ:<a href='https://seekingalpha.com/symbol/LILAK' title='Liberty Global, Inc.'>LILAK</a>) is jumping, <font color=\"green\">up 3%</font>, following a Reuters report that the company has approached Millicom (NASDAQ:<a href='https://seekingalpha.com/symbol/TIGO' title='Millicom International Cellular SA'>TIGO</a>) with a <a href=\"https://www.reuters.com/article/us-millicom-m-a-libertylatinamerica-excl/exclusive-liberty-latin-america-in-bid-to-acquire-millicom-sources-idUSKCN1P820D?il=0\" target=\"_blank\">takeover bid</a>.</li>    <li>Millicom's Nasdaq shares are <font color=\"green\">up 8.1%</font>.</li>    <li>John Malone's wireless/cable operator has been in talks with Millicom (focused on Latin America and Africa) for weeks, according to the news service.</li>    <li>Millicom last week <a href=\"https://seekingalpha.com/news/3421917-millicom-updates-latin-america-guidance-begins-nasdaq-trading\" target=\"_blank\">updated guidance</a> as it began trading common shares on Nasdaq.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3422794\" data-linked=\"Reuters: Liberty Latin America bidding for Millicom; shares jump\" data-tweet=\"$LILAK $LILAK $TIGO - Reuters: Liberty Latin America bidding for Millicom; shares jump https://seekingalpha.com/news/3422794-reuters-liberty-latin-america-bidding-for-millicom-shares-jump?source=tweet\" data-url=\"https://seekingalpha.com/news/3422794-reuters-liberty-latin-america-bidding-for-millicom-shares-jump\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422790\" data-ts=\"1547484525\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CODX\" target=\"_blank\">CODX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422790-co-diagnostics-up-15-on-coprimers-presentation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Co-Diagnostics up 15% on CoPrimers presentation</a></h4><ul><li>Thinly traded nano cap Co-Diagnostics (<a href='https://seekingalpha.com/symbol/CODX' title='Co-Diagnostics'>CODX</a> <font color=\"green\">+15.3%</font>) is up on a healthy 21x surge in volume, albeit on turnover of only 446K shares. Today, a company scientist is <a href=\"https://seekingalpha.com/pr/17376254-co-diagnostics-inc-present-pag-xxvii-january-14-san-diego\" target=\"_blank\">presenting </a>research on the SNP genotyping and multiplex capabilities of CoPrimers at the International Plant and Genome Conference in San Diego.</li><li>On the working capital front, at the end of September 2018, it had $2.2M in cash and equivalents while operations consumed $3.1M during the first three quarters of the year.</li><li>In August 2018, it filed a <a href=\"https://www.sec.gov/Archives/edgar/data/1692415/000149315218011879/forms-3.htm\" target=\"_blank\">prospectus </a>for a $25M mixed shelf offering.</li></ul><div class=\"tiny-share-widget\" data-id=\"3422790\" data-linked=\"Co-Diagnostics up 15% on CoPrimers presentation\" data-tweet=\"$CODX - Co-Diagnostics up 15% on CoPrimers presentation https://seekingalpha.com/news/3422790-co-diagnostics-up-15-on-coprimers-presentation?source=tweet\" data-url=\"https://seekingalpha.com/news/3422790-co-diagnostics-up-15-on-coprimers-presentation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:48 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422787\" data-ts=\"1547483963\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBLI\" target=\"_blank\">CBLI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422787-cleveland-biolabs-up-34\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cleveland BioLabs up 34%</a></h4><ul><li>Ultra-thinly traded nano cap Cleveland BioLabs (<a href='https://seekingalpha.com/symbol/CBLI' title='Cleveland BioLabs, Inc.'>CBLI</a> <font color=\"green\">+33.8%</font>) is up on double normal volume, albeit on turnover of only 17K shares, on no particular news.</li><li>At the end of September 2018, it $5.3M in quick assets while operations consumed $3.4M during the first three quarters of the year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3422787\" data-linked=\"Cleveland BioLabs up 34%\" data-tweet=\"$CBLI - Cleveland BioLabs up 34% https://seekingalpha.com/news/3422787-cleveland-biolabs-up-34?source=tweet\" data-url=\"https://seekingalpha.com/news/3422787-cleveland-biolabs-up-34\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:39 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422784\" data-ts=\"1547483263\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WDC\" target=\"_blank\">WDC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422784-wdc-on-worst-day-since-october-evercore-frets-dividend\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WDC on worst day since October as Evercore frets dividend</a></h4><ul>   <li>Western Digital (NYSE:<a href='https://seekingalpha.com/symbol/WDC' title='Western Digital Corporation'>WDC</a>) has <font color=\"red\">slipped 7.6%</font> in its worst day since October, and touched a two-week low, after Evercore cut its rating to Underperform on worries about a dividend cut.</li>    <li>Free cash flow is tracking to about $2.35/share or lower this year, and \"combined with $11b in gross debt ($6.5b net debt), we see clear risk to the current annual dividend of $2.00,\" analyst C.J. Muse writes. (h/t Bloomberg)</li>    <li>Muse is \"hard pressed\" to see the dividend sustainable under current conditions. The firm's cut its price target to $30 from $35, implying 19% further downside.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3422784\" data-linked=\"WDC on worst day since October as Evercore frets dividend\" data-tweet=\"$WDC - WDC on worst day since October as Evercore frets dividend https://seekingalpha.com/news/3422784-wdc-on-worst-day-since-october-evercore-frets-dividend?source=tweet\" data-url=\"https://seekingalpha.com/news/3422784-wdc-on-worst-day-since-october-evercore-frets-dividend\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422781\" data-ts=\"1547483038\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RNN\" target=\"_blank\">RNN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422781-rexahn-up-16-ahead-of-updated-rxminus-3117-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rexahn up 16% ahead of updated RX-3117 data</a></h4><ul><li>Thinly traded nano cap Rexahn Pharmaceuticals (<a href='https://seekingalpha.com/symbol/RNN' title='Rexahn Pharmaceuticals Inc'>RNN</a> <font color=\"green\">+16.3%</font>) is up on nearly four times normal volume. On Friday, it will present <a href=\"https://seekingalpha.com/pr/17378657-rexahn-announces-presentation-rxminus-3117-data-2019-asco-gastrointestinal-cancers-symposium\" target=\"_blank\">updated data</a> from a <a href=\"https://clinicaltrials.gov/ct2/show/NCT03189914?lead=rexahn&amp;rank=1\" target=\"_blank\">Phase 2a clinical trial </a>evaluating the combination of RX-3117 and Celgene's Abraxane (paclitaxel/nab-paclitaxel) in first-line pancreatic cancer at the ASCO GI Cancers Symposium in San Francisco.</li><li>In October 2018, it <a href=\"https://seekingalpha.com/news/3394397-rexahn-pharmas-rxminus-3117-shows-positive-action-mid-stage-pancreatic-cancer-study-shares-4\" target=\"_blank\">reported </a>a 29% (n=4/14) response rate and 86% (n=12/14) disease control rate.</li></ul><div class=\"tiny-share-widget\" data-id=\"3422781\" data-linked=\"Rexahn up 16% ahead of updated RX-3117 data\" data-tweet=\"$RNN $REXN - Rexahn up 16% ahead of updated RX-3117 data https://seekingalpha.com/news/3422781-rexahn-up-16-ahead-of-updated-rxminus-3117-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3422781-rexahn-up-16-ahead-of-updated-rxminus-3117-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:23 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422779\" data-ts=\"1547482941\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEUM\" target=\"_blank\">TEUM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422779-shutdown-spurs-pareteum-to-extend-tender-for-ipass\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shutdown spurs Pareteum to extend tender for iPass</a></h4><ul>   <li>Pareteum (<a href=\"http://seekingalpha.com/symbol/TEUM\" target=\"_blank\">TEUM</a> <font color=\"green\">+0.7%</font>) has <a href=\"https://seekingalpha.com/pr/17378428-pareteum-extends-tender-offer-outstanding-shares-ipass\" target=\"_blank\">extended a tender offer</a> for all outstanding shares of iPass (<a href=\"http://seekingalpha.com/symbol/IPAS\" target=\"_blank\">IPAS</a> <font color=\"green\">+2.8%</font>) due to the government shutdown.</li>    <li>That's caused delays with Pareteum's registration statement.</li>    <li>The tender is now set to expire at 5 p.m. New York City time on Feb. 12.</li>    <li>As of the end of Friday, some 4,949,254 shares were validly tendered, about 58.7% of outstanding iPass shares.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3422779\" data-linked=\"Shutdown spurs Pareteum to extend tender for iPass\" data-tweet=\"$TEUM $TEUM $IPAS - Shutdown spurs Pareteum to extend tender for iPass https://seekingalpha.com/news/3422779-shutdown-spurs-pareteum-to-extend-tender-for-ipass?source=tweet\" data-url=\"https://seekingalpha.com/news/3422779-shutdown-spurs-pareteum-to-extend-tender-for-ipass\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422777\" data-ts=\"1547482518\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PCG\" target=\"_blank\">PCG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422777-pg-and-e-bonds-plunge-spreads-widen-on-chapter-11-plan\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PG&amp;E bonds plunge, spreads widen on Chapter 11 plan</a></h4><ul><li>PG&amp;E (<a href='https://seekingalpha.com/symbol/PCG' title='PG&E Corporation'>PCG</a> <font color='red'>-48.8%</font>) plunges by ~50% after unveiling a plan to <a href=\"https://seekingalpha.com/news/3422615-pg-and-e-file-chapter-11-bankruptcy\" target=\"_blank\">seek bankruptcy protection</a> amid mountainous liabilities linked to California wildfires.</li><li>Nearly all of PG&amp;E\u2019s ~$18B of bonds were <a href=\"https://www.reuters.com/article/us-pg-e-us-bankruptcy-bonds/pge-bond-prices-fall-spreads-widen-on-bankruptcy-plans-idUSKCN1P81PZ\" target=\"_blank\">trading sharply lower</a>, sending their yields to record highs, Reuters reports, citing data from MarketAxess.</li><li>The drops are particularly large among its nearest maturities, with bonds maturing in October 2020 and May 2021 both falling by more than 7 points in price, with their yield spreads surging to 12.65 and 11.16 percentage points, respectively, much higher than the 4.5 percentage point average spread of high-yield notes over Treasuries.</li><li>Eight of the top 10 most-traded U.S. corporate bonds this morning belong to PG&amp;E, with the most actively traded a $3B note coming due in March 2034, according to MarketAxess.</li></ul><div class=\"tiny-share-widget\" data-id=\"3422777\" data-linked=\"PG&amp;E bonds plunge, spreads widen on Chapter 11 plan\" data-tweet=\"$PCG - PG&amp;E bonds plunge, spreads widen on Chapter 11 plan https://seekingalpha.com/news/3422777-pg-and-e-bonds-plunge-spreads-widen-on-chapter-11-plan?source=tweet\" data-url=\"https://seekingalpha.com/news/3422777-pg-and-e-bonds-plunge-spreads-widen-on-chapter-11-plan\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>76&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422773\" data-ts=\"1547482074\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMGN\" target=\"_blank\">AMGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422773-fda-ad-com-approaches-for-amgens-osteoporosis-med-romosozumab\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA Ad Com approaches for Amgen&#39;s osteoporosis med romosozumab</a></h4><ul><li>The FDA's Bone, Reproductive and Urologic Drugs Advisory Committee will <a href=\"https://www.fda.gov/AdvisoryCommittees/Calendar/ucm627359.htm\" target=\"_blank\">meet </a>on Wednesday, January 16, to review and discuss Amgen's (<a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a> <font color=\"red\">-1.4%</font>) resubmitted marketing application seeking approval for EVENITY (romosozumab) injection for the treatment of osteoporosis in postmenopausal women at high risk for fracture.</li><li>The company received a CRL in July 2017 citing the need to further evaluate the cardiovascular &#40;CV&#41; risk.</li><li>Due to the safety signal, Amgen is now proposing the narrower indication (originally osteoporosis in postmenopausal women), a Boxed Warning and a Warning and Precaution for CV risk. Efficacy is not in question.</li><li><a href=\"https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM629456.pdf\" target=\"_blank\">FDA briefing doc</a></li><li><a href=\"https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM629457.pdf\" target=\"_blank\">Errata to FDA briefing doc</a></li><li><a href=\"https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM629458.pdf\" target=\"_blank\">Amgen briefing doc </a></li></ul><div class=\"tiny-share-widget\" data-id=\"3422773\" data-linked=\"FDA Ad Com approaches for Amgen&#39;s osteoporosis med romosozumab\" data-tweet=\"$AMGN - FDA Ad Com approaches for Amgen&#39;s osteoporosis med romosozumab https://seekingalpha.com/news/3422773-fda-ad-com-approaches-for-amgens-osteoporosis-med-romosozumab?source=tweet\" data-url=\"https://seekingalpha.com/news/3422773-fda-ad-com-approaches-for-amgens-osteoporosis-med-romosozumab\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:07 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422770\" data-ts=\"1547481913\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MBOT\" target=\"_blank\">MBOT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422770-microbot-medical-leads-healthcare-gainers-verona-pharma-and-prestige-consumer-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Microbot Medical leads healthcare gainers; Verona Pharma and Prestige Consumer Healthcare among losers</a></h4><ul><li><b>Gainers: </b>Microbot Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/MBOT' title='Microbot Medical Inc'>MBOT</a>) <font color=\"green\">+192%</font>. Cleveland BioLabs (NASDAQ:<a href='https://seekingalpha.com/symbol/CBLI' title='Cleveland BioLabs, Inc.'>CBLI</a>) <font color=\"green\">+21%</font>. VIVUS (NASDAQ:<a href='https://seekingalpha.com/symbol/VVUS' title='Vivus, Inc.'>VVUS</a>) <font color=\"green\">+21%</font>. Co-Diagnostics (NASDAQ:<a href='https://seekingalpha.com/symbol/CODX' title='Co-Diagnostics'>CODX</a>) <font color=\"green\">+17%</font>. Rexahn Pharmaceuticals (NYSEMKT:<a href='https://seekingalpha.com/symbol/RNN' title='Rexahn Pharmaceuticals Inc'>RNN</a>) <font color=\"green\">+15%</font>.</li><li><b>Losers: </b>Verona Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/VRNA' title='Verona Pharma plc'>VRNA</a>) <font color=\"red\">-40%</font>. Prestige Consumer Healthcare (NYSE:<a href='https://seekingalpha.com/symbol/PBH' title='Prestige Brands Holdings, Inc.'>PBH</a>) <font color=\"red\">-13%</font>. ASLAN Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ASLN' title='ASLAN Pharmaceuticals'>ASLN</a>) <font color=\"red\">-11%</font>. Enochian Biosciences (<a href='https://seekingalpha.com/symbol/ENOB' title='Enochian Biosciences Inc.'>OTCQB:ENOB</a>) <font color=\"red\">-8%</font>. PLx Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/PLXP' title='PLx Pharma'>PLXP</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3422770\" data-linked=\"Microbot Medical leads healthcare gainers; Verona Pharma and Prestige Consumer Healthcare among losers\" data-tweet=\"$MBOT $MBOT $CBLI - Microbot Medical leads healthcare gainers; Verona Pharma and Prestige Consumer Healthcare among losers https://seekingalpha.com/news/3422770-microbot-medical-leads-healthcare-gainers-verona-pharma-and-prestige-consumer-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3422770-microbot-medical-leads-healthcare-gainers-verona-pharma-and-prestige-consumer-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:05 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422769\" data-ts=\"1547481737\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SBGL\" target=\"_blank\">SBGL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422769-strike-against-sibanye-stillwater-expanded-to-platinum-operations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Strike against Sibanye-Stillwater expanded to platinum operations</a></h4><ul><li>Sibanye-Stillwater (<a href='https://seekingalpha.com/symbol/SBGL' title='Sibanye-Stillwater'>SBGL</a> <font color='red'>-5.9%</font>) plunges after the AMCU union says ~12.5K of its members would <a href=\"https://af.reuters.com/article/investingNews/idAFKCN1P81H1-OZABS\" target=\"_blank\">go on strike at the company\u2019s platinum operations</a> beginning Jan. 22, expanding an earlier strike  affecting gold operations.</li><li>15K AMCU members have been on strike at SBGL\u2019s gold operations since mid-November after wage talks broke down.</li><li>SBGL says it is unable to estimate the impact of the strike's expansion would have on operations at its South African platinum mines; AMCU is the majority union at all of the company\u2019s local platinum mines.</li></ul><div class=\"tiny-share-widget\" data-id=\"3422769\" data-linked=\"Strike against Sibanye-Stillwater expanded to platinum operations\" data-tweet=\"$SBGL - Strike against Sibanye-Stillwater expanded to platinum operations https://seekingalpha.com/news/3422769-strike-against-sibanye-stillwater-expanded-to-platinum-operations?source=tweet\" data-url=\"https://seekingalpha.com/news/3422769-strike-against-sibanye-stillwater-expanded-to-platinum-operations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>89&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422766\" data-ts=\"1547481421\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VNCE\" target=\"_blank\">VNCE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422766-vince-holding-rallies-after-holiday-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vince Holding rallies after holiday update</a></h4><ul> <li>Vince Holding (<a href='https://seekingalpha.com/symbol/VNCE' title='Vince Holding Corp.'>VNCE</a> <font color='green'>+5.5%</font>) announces sales increased 11.9% Y/Y during the nine-week holiday period.</li>     <li>Direct-to-consumer segment sales were up 13.2%, driven by comparable       sales growth of 8.2% and the opening of four net new stores from a year ago. On a shifted basis, comparable sales       increased 6.3%.</li>     <li>CEO sales update: \"We saw solid sales       performance during the holiday season as new product continues to be       well-received by customers in our Direct-to-Consumer and Wholesale       segments. In our Wholesale segment, we are seeing market share gains       within our accounts as evidenced by double-digit sales growth at the       retail level. We remain focused on advancing the strategic initiatives       that we believe will enable us to deliver long term sustainable growth.\"</li>     <li>Source: <a href=\"https://seekingalpha.com/pr/17378523-vince-holding-corp-provides-holiday-sales-performance-update\" target=\"_blank\">Press Release</a></li><li>#ICR19</li></ul><div class=\"tiny-share-widget\" data-id=\"3422766\" data-linked=\"Vince Holding rallies after holiday update\" data-tweet=\"$VNCE - Vince Holding rallies after holiday update https://seekingalpha.com/news/3422766-vince-holding-rallies-after-holiday-update?source=tweet\" data-url=\"https://seekingalpha.com/news/3422766-vince-holding-rallies-after-holiday-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:57 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422765\" data-ts=\"1547481001\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/USAT\" target=\"_blank\">USAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422765-usa-tech-shakes-up-management-audit-nearing-finish-line-shares-up-22\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">USA Tech shakes up management, audit nearing the finish line; shares up 22%</a></h4><ul><li>UAS Technologies (<a href='https://seekingalpha.com/symbol/USAT' title='USA Technologies, Inc.'>USAT</a> <font color=\"green\">+22.1%</font>) is up on double normal volume. Shares are up over <font color=\"green\">90%</font> since late December.</li><li>In a <a href=\"https://www.sec.gov/Archives/edgar/data/896429/000114036119000855/form8k.htm\" target=\"_blank\">regulatory filing</a> posted today, it disclosed a management shakeup effective yesterday. Chief Services Officer Michael Lawlor is no longer in the position, but will serve as a consultant for an unspecified term. SVP of Marketing and Strategic Development Maeve Duska has been reassigned as has SVP of Operations George Harrum.</li><li>Its internal investigation into certain contractual arrangements in 2017 and 2018 is almost finished. It appears that the company prematurely recognized revenue and, in some cases, the reported number of connections associated with the transactions.</li><li>Once the audit is completed and adjustments made, it plans to file its Q4 10-Q and 2018 annual report.</li></ul><div class=\"tiny-share-widget\" data-id=\"3422765\" data-linked=\"USA Tech shakes up management, audit nearing the finish line; shares up 22%\" data-tweet=\"$USAT - USA Tech shakes up management, audit nearing the finish line; shares up 22% https://seekingalpha.com/news/3422765-usa-tech-shakes-up-management-audit-nearing-finish-line-shares-up-22?source=tweet\" data-url=\"https://seekingalpha.com/news/3422765-usa-tech-shakes-up-management-audit-nearing-finish-line-shares-up-22\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422759\" data-ts=\"1547480294\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GCI\" target=\"_blank\">GCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422759-gannettplus-15_5-on-1_36b-bid-from-mng\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gannett +15.5% on $1.36B bid from MNG</a></h4><ul>   <li>Gannett (NYSE:<a href='https://seekingalpha.com/symbol/GCI' title='Gannett Co., Inc.'>GCI</a>) is <font color=\"green\">up 15.5%</font> after a <a href=\"https://seekingalpha.com/pr/17378456-mng-enterprises-proposes-acquire-gannett-12_00-per-share-cash\" target=\"_blank\">hostile $1.36B bid</a> arrives from MNG/Digital First.</li>    <li>That's a $12/share cash offer, vs. Friday's closing price of $9.75. MNG is asking Gannett to enter discussions immediately about a strategic combination.</li>    <li>It's also asking for a review of strategic alternatives, and a moratorium on acquiring additional digital assets, as well as holding off on a new CEO until it commits to a \"feasible, strategic and financial path forward.\"</li>    <li>The stock has lost 41% of value since the Tegna spin-off, MNG notes in its letter, meaning the team leading Gannett hasn't demonstrated it's capable of effectively running it as a public company.</li>    <li>Gannett has <a href=\"https://seekingalpha.com/pr/17378877-gannett-comments-proposal-mng-enterprises-inc\" target=\"_blank\">acknowledged receiving the bid</a> and says it will carefully review it.</li>    <li>MNG owns and operates one of the country's biggest newspaper businesses, with about 200 publications.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3422759\" data-linked=\"Gannett +15.5% on $1.36B bid from MNG\" data-tweet=\"$GCI - Gannett +15.5% on $1.36B bid from MNG https://seekingalpha.com/news/3422759-gannettplus-15_5-on-1_36b-bid-from-mng?source=tweet\" data-url=\"https://seekingalpha.com/news/3422759-gannettplus-15_5-on-1_36b-bid-from-mng\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422751\" data-ts=\"1547479707\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/USPH\" target=\"_blank\">USPH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422751-u-s-physical-therapy-down-2-on-cautious-mention-research-firm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">U.S. Physical Therapy down 2% on cautious mention by research firm</a></h4><ul><li>Thinly traded U.S. Physical Therapy (<a href='https://seekingalpha.com/symbol/USPH' title='U.S. Physical Therapy, Inc.'>USPH</a> <font color=\"red\">-2.3%</font>) is down on light volume in early trade in apparent response to a cautious mention by independent shop <a href=\"https://www.pacificsquareresearch.com/\" target=\"_blank\">Pacific Square Research</a> who believes that the company has <a href=\"https://mail.google.com/mail/u/0/#inbox/FMfcgxwBVDJgwdJzjmbvDDmjZcccGZTg\" target=\"_blank\">serious accounting issues</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3422751\" data-linked=\"U.S. Physical Therapy down 2% on cautious mention by research firm\" data-tweet=\"$USPH - U.S. Physical Therapy down 2% on cautious mention by research firm https://seekingalpha.com/news/3422751-u-s-physical-therapy-down-2-on-cautious-mention-research-firm?source=tweet\" data-url=\"https://seekingalpha.com/news/3422751-u-s-physical-therapy-down-2-on-cautious-mention-research-firm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422747\" data-ts=\"1547479562\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IQ\" target=\"_blank\">IQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422747-iqiyi-slips-6-bernstein-assumes-underperform\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">IQiyi slips 6% as Bernstein assumes at Underperform</a></h4><ul>   <li>IQiyi (NASDAQ:<a href='https://seekingalpha.com/symbol/IQ' title='iQIYI, Inc'>IQ</a>) is <font color=\"red\">6.1% lower</font> in Nasdaq trading after Bernstein assumes coverage at Underperform.</li>    <li>The firm set its price target on the ADRs to $11, implying a further 34% downside from current pricing.</li>    <li>Meanwhile, OTR Global has downgraded the stock to Mixed.</li>    <li>After an initial pop early last summer, shares have been on a multi-month downtrend, <font color=\"red\">falling 49.1%</font> over the past six months.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3422747\" data-linked=\"IQiyi slips 6% as Bernstein assumes at Underperform\" data-tweet=\"$IQ - IQiyi slips 6% as Bernstein assumes at Underperform https://seekingalpha.com/news/3422747-iqiyi-slips-6-bernstein-assumes-underperform?source=tweet\" data-url=\"https://seekingalpha.com/news/3422747-iqiyi-slips-6-bernstein-assumes-underperform\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>34&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422745\" data-ts=\"1547479420\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CDLX\" target=\"_blank\">CDLX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422745-cardlyticsplus-6-on-preliminary-q418-financial-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cardlytics +6% on preliminary Q418 financial results</a></h4><ul><li>Cardlytics (<a href='https://seekingalpha.com/symbol/CDLX' title='Cardlytics, Inc.'>CDLX</a> <font color=\"green\">+6.3%</font>) <a href=\"https://seekingalpha.com/pr/17378752-cardlytics-announces-preliminary-fourth-quarter-2018-financial-results\" target=\"_blank\">expects</a> Q4 revenue in the range of $47M - $48M vs. a consensus of $44.14M.</li><li>Scott Grimes, CEO &amp; Co-Founder of Cardlytics: \u201cWe are pleased with our revenue performance in the fourth quarter, which is expected to be above our prior guidance. In addition, we had strong MAU growth in the Q4 and expect that growth to continue into 2019\".</li><li>The Company will report Q418 results on March 5, 2019.</li></ul><div class=\"tiny-share-widget\" data-id=\"3422745\" data-linked=\"Cardlytics +6% on preliminary Q418 financial results\" data-tweet=\"$CDLX - Cardlytics +6% on preliminary Q418 financial results https://seekingalpha.com/news/3422745-cardlyticsplus-6-on-preliminary-q418-financial-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3422745-cardlyticsplus-6-on-preliminary-q418-financial-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:23 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422742\" data-ts=\"1547479228\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALDR\" target=\"_blank\">ALDR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422742-alder-bio-nice-bolt-on-leerink\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alder Bio a nice bolt-on - Leerink</a></h4><ul><li>Alder Biopharmaceuticals (<a href='https://seekingalpha.com/symbol/ALDR' title='Alder Biopharmaceuticals Inc.'>ALDR</a> <font color=\"green\">+3.6%</font>) is up on light volume in early trade. Leerink's Geoffrey Porges says the company is an <a href=\"https://endpts.com/buzz-this-little-biotech-has-so-much-going-against-it-somebody-is-going-to-want-to-buy-it-right/\" target=\"_blank\">attractive target</a> for a larger outfit looking for a bolt-on acquisition considering its modest $769M market cap. It's a tiny biotech with one main product candidate, eptinezumab, a Phase 3-stage intravenous therapy for chronic and episodic migraine.</li><li>It is apparently in discussions with potential partners for commercialization in Europe and other markets.</li><li>He believes Biogen (<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a> <font color=\"red\">-1.2%</font>) would be a great fit in light of its need for deals and its footprint in neurology.</li></ul><div class=\"tiny-share-widget\" data-id=\"3422742\" data-linked=\"Alder Bio a nice bolt-on - Leerink\" data-tweet=\"$ALDR $ALDR $BIIB - Alder Bio a nice bolt-on - Leerink https://seekingalpha.com/news/3422742-alder-bio-nice-bolt-on-leerink?source=tweet\" data-url=\"https://seekingalpha.com/news/3422742-alder-bio-nice-bolt-on-leerink\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422741\" data-ts=\"1547479103\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DXLG\" target=\"_blank\">DXLG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422741-retail-gets-lift-from-icr\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Retail gets a lift from ICR</a></h4><ul> <li>Positive updates from ICR have sent Destination XL Group (<a href='https://seekingalpha.com/symbol/DXLG' title='Destination XL Group, Inc.'>DXLG</a> <font color=\"green\">+12.9%</font>), Boot Barn (<a href='https://seekingalpha.com/symbol/BOOT' title='Boot Barn Holdings'>BOOT</a> <font color=\"green\">+12%</font>), Lululemon (<a href='https://seekingalpha.com/symbol/LULU' title='Lululemon Athletica Inc.'>LULU</a> <font color=\"green\">+7.1%</font>), American Eagle Outfitters (<a href='https://seekingalpha.com/symbol/AEO' title='American Eagle Outfitters, Inc.'>AEO</a> <font color=\"green\">+3.8%</font>), Tilly's (<a href='https://seekingalpha.com/symbol/TLYS' title='Tilly&#39;s, Inc.'>TLYS</a> <font color=\"green\">+2.9%</font>) and Denny's (<a href='https://seekingalpha.com/symbol/DENN' title='Denny&#39;s Corporation'>DENN</a> <font color=\"green\">+1.7%</font>) all higher in morning trading.</li> <li>The positive vibe from ICR has been enough to lift the S&amp;P Retail ETF (NYSEARCA:<a href='https://seekingalpha.com/symbol/XRT' title='SPDR S&P Retail ETF'>XRT</a>) <font color=\"green\">0.2%</font>, even with broad market averages showing declines.</li> <li>#ICR19</li><li>ETFs: <a href='https://seekingalpha.com/symbol/XLY' title='Consumer Discretionary Select Sector SPDR ETF'>XLY</a>, <a href='https://seekingalpha.com/symbol/XRT' title='SPDR S&P Retail ETF'>XRT</a>, <a href='https://seekingalpha.com/symbol/VCR' title='Vanguard Consumer Discretionary ETF'>VCR</a>, <a href='https://seekingalpha.com/symbol/RTH' title='VanEck Vectors Retail ETF'>RTH</a>, <a href='https://seekingalpha.com/symbol/RETL' title='Direxion Daily Retail Bull 3x Shares ETF'>RETL</a>, <a href='https://seekingalpha.com/symbol/FDIS' title='Fidelity MSCI Consumer Discretionary Index ETF'>FDIS</a>, <a href='https://seekingalpha.com/symbol/FXD' title='First Trust Consumer Discretionary AlphaDEX ETF'>FXD</a>, <a href='https://seekingalpha.com/symbol/IYC' title='iShares U.S. Consumer Services ETF'>IYC</a>, <a href='https://seekingalpha.com/symbol/EMTY' title='ProShares Decline of the Retail Store ETF'>EMTY</a>, <a href='https://seekingalpha.com/symbol/SCC' title='ProShares UltraShort Consumer Services ETF'>SCC</a>, <a href='https://seekingalpha.com/symbol/RCD' title='Invesco S&P Equal Weight Consumer Discretionary ETF'>RCD</a>, <a href='https://seekingalpha.com/symbol/UCC' title='ProShares Ultra Consumer Services ETF'>UCC</a>, <a href='https://seekingalpha.com/symbol/PMR' title='Invesco Dynamic Retail Portfolio ETF'>PMR</a>, <a href='https://seekingalpha.com/symbol/FTXD' title='First Trust Nasdaq Retail ETF'>FTXD</a>, <a href='https://seekingalpha.com/symbol/JHMC' title='John Hancock Multifactor Consumer Discretionary ETF'>JHMC</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3422741\" data-linked=\"Retail gets a lift from ICR\" data-tweet=\"$DXLG $DXLG $BOOT - Retail gets a lift from ICR https://seekingalpha.com/news/3422741-retail-gets-lift-from-icr?source=tweet\" data-url=\"https://seekingalpha.com/news/3422741-retail-gets-lift-from-icr\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422739\" data-ts=\"1547478785\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IPIC\" target=\"_blank\">IPIC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422739-ipic-entertainment-announces-preliminary-sales-and-2019-financial-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">iPic® Entertainment announces preliminary sales and 2019 financial outlook</a></h4><ul><li>iPic® Entertainment (<a href='https://seekingalpha.com/symbol/IPIC' title='iPic Entertainment Inc.'>IPIC</a> <font color='red'>-1.3%</font>) <a href=\"https://seekingalpha.com/pr/17378531-ipic-entertainment-announces-preliminary-fourth-quarter-and-full-year-2018-sales-results\" target=\"_blank\">expects</a> Q4 revenue in the range of $36.5M - $37.5M (previous guidance $34.5M - $36.5m) vs. a consensus of $36.17M; Comparable-store sales growth of 1.5% - 2.0% (previous guidance -5.0% - 0.0%).</li><li><strong>Full Year 2018 Sales Results: </strong>Total revenue of $143.0M - $144.0M (previous guidance $141M - $143M) vs. a consensus of $142.69M; Comparable-store sales growth of 1.6% - 2.0% (previous guidance 0.0% - 1.0%).</li><li><strong>Initial FY19 financial outlook: </strong>Total revenue of $153M - $158M (~+7% - 11% Y/Y) vs. a consensus of $159.94M; Comparable-store sales growth of low-to-mid single digits; Store-level EBITDA, a non-GAAP measure, of $19M to $21M; Adjusted EBITDA, a non-GAAP measure, of $(3.0)M to $(1.0)M; Capital expenditures of $17M - $19M, net of tenant improvement dollars, marking a substantial decrease from 2018.</li></ul><div class=\"tiny-share-widget\" data-id=\"3422739\" data-linked=\"iPic® Entertainment announces preliminary sales and 2019 financial outlook\" data-tweet=\"$IPIC $IPICQ - iPic® Entertainment announces preliminary sales and 2019 financial outlook https://seekingalpha.com/news/3422739-ipic-entertainment-announces-preliminary-sales-and-2019-financial-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3422739-ipic-entertainment-announces-preliminary-sales-and-2019-financial-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422731\" data-ts=\"1547478105\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRXC\" target=\"_blank\">TRXC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422731-fda-oks-transenterix-senhance-ultrasonic-system-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs TransEnterix Senhance Ultrasonic System; shares up 1%</a></h4><ul><li>The FDA <a href=\"https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K182421\" target=\"_blank\">grants </a>510(k) clearance for TransEnterix's (<a href='https://seekingalpha.com/symbol/TRXC' title='TransEnterix, Inc.'>TRXC</a>) <a href=\"https://www.senhance.com/us/digital-laparoscopy\" target=\"_blank\">Senhance Ultrasonic System</a>, its digital laparoscopy device. It was CE Mark'd in October 2018.</li><li>Shares are up <font color=\"green\">1%</font> in early trade.</li></ul><div class=\"tiny-share-widget\" data-id=\"3422731\" data-linked=\"FDA OKs TransEnterix Senhance Ultrasonic System; shares up 1%\" data-tweet=\"$TRXC - FDA OKs TransEnterix Senhance Ultrasonic System; shares up 1% https://seekingalpha.com/news/3422731-fda-oks-transenterix-senhance-ultrasonic-system-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3422731-fda-oks-transenterix-senhance-ultrasonic-system-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422719\" data-ts=\"1547477096\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CY\" target=\"_blank\">CY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422719-semi-targets-trimmed-morgan-stanley\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Semi targets trimmed at Morgan Stanley</a></h4><ul><li>\"Growth disappointed in December across the board, including autos, industrial and smartphones,\" says analyst Craig Hettenbach, who expects another round of estimate cuts alongside Q1 earnings.</li><li>He cuts his price target on Cypress Semi (<a href='https://seekingalpha.com/symbol/CY' title='Cypress Semiconductor Corporation'>CY</a> <font color='red'>-3.2%</font>) to $11.50 from $12, NXP Semi (<a href='https://seekingalpha.com/symbol/NXPI' title='NXP Semiconductors'>NXPI</a> <font color='red'>-1.6%</font>) to $95 from $100, and Maxim Integrated (<a href='https://seekingalpha.com/symbol/MXIM' title='Maxim Integrated Products, Inc.'>MXIM</a> <font color='red'>-2.2%</font>) to $51 from $53.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3422719\" data-linked=\"Semi targets trimmed at Morgan Stanley\" data-tweet=\"$CY $CY $NXPI - Semi targets trimmed at Morgan Stanley https://seekingalpha.com/news/3422719-semi-targets-trimmed-morgan-stanley?source=tweet\" data-url=\"https://seekingalpha.com/news/3422719-semi-targets-trimmed-morgan-stanley\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422716\" data-ts=\"1547476897\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STX\" target=\"_blank\">STX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422716-seagate-drops-3-on-western-digital-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Seagate drops 3% on Western Digital downgrade</a></h4><ul><li>Western Digital is <font color=\"red\">down nearly 9% </font>after Evercore <a href=\"https://seekingalpha.com/news/3422690-evercore-softens-view-western-digital-premarket-analyst-action\" target=\"_blank\">downgraded to Underpeform</a>, noting the company's dividend is at risk of being cut.</li><li>That's stinging competitor Seagate (NASDAQ:<a href='https://seekingalpha.com/symbol/STX' title='Seagate Technology'>STX</a>) as well, which is <font color=\"red\">lower by 3.15%</font> in early action.</li></ul><div class=\"tiny-share-widget\" data-id=\"3422716\" data-linked=\"Seagate drops 3% on Western Digital downgrade\" data-tweet=\"$STX - Seagate drops 3% on Western Digital downgrade https://seekingalpha.com/news/3422716-seagate-drops-3-on-western-digital-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3422716-seagate-drops-3-on-western-digital-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422714\" data-ts=\"1547476851\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SJR\" target=\"_blank\">SJR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422714-shaw-communicationsplus-3_3-post-q1-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shaw Communications +3.3% post Q1 results</a></h4><ul><li>Shaw Communications (<a href='https://seekingalpha.com/symbol/SJR' title='Shaw Communications Inc.'>SJR</a> <font color=\"green\">+3.2%</font>) reports <a href=\"https://seekingalpha.com/pr/17378763-shaw-announces-first-quarter-fiscal-2019-results\" target=\"_blank\">Q1</a> revenue growth of 8.8% Y/Y to C$1.36B.</li><li>Subscribers: Wireline of 5.63M (-0.9% Q/Q); Wireless of 1.47M (+5% Q/Q) &amp; Total of 7.09M (+0.1% Q/Q).</li><li>The Company continued to add wireless subscribers, gaining a net combined 65,615 postpaid and prepaid subscribers.</li><li>Operating margin <font color=\"green\">increased 160 bps</font> to 40.2%</li><li>Net debt leverage ratio of 2.0x &amp; Free cash flow of C$164M, increased $100M Y/Y.</li><li>When combined with existing corporate and dealer store network, Freedom Mobile expects to have ~600 retail locations operational at the end of the quarter.</li><li><strong>2019 Outlook:</strong> Consolidated operating income to growth 4-6%; capital investments of ~C$1.2B; and free cash flow of ~C$500M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3422654-shaw-communications-beats-c-0_05-beats-revenue\" target=\"_blank\">Shaw Communications beats by C$0.05, beats on revenue</a> (Jan. 14 2019)</li></ul><div class=\"tiny-share-widget\" data-id=\"3422714\" data-linked=\"Shaw Communications +3.3% post Q1 results\" data-tweet=\"$SJR - Shaw Communications +3.3% post Q1 results https://seekingalpha.com/news/3422714-shaw-communicationsplus-3_3-post-q1-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3422714-shaw-communicationsplus-3_3-post-q1-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:40 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422708\" data-ts=\"1547476395\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MU\" target=\"_blank\">MU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422708-micronminus-4_3-morgan-stanley-sees-no-2019-rebound\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Micron -4.3% as Morgan Stanley sees no 2019 rebound</a></h4><ul>   <li>Micron (NASDAQ:<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology Inc.'>MU</a>) has come out of today's open <font color=\"red\">down 4.3%</font> after Morgan Stanley warns about continued doldrums in the shares despite months of declines.</li>    <li>\"While we see value in the stock, we don\u2019t see a rebound at any point in 2019,\" writes analyst Joseph Moore, and the firm is cautious on semiconductors overall. But: \"There remains too much fundamental optimism in our investor conversations around Micron in the short term.\" (h/t Bloomberg)</li>    <li>Shares have fallen more than 40% since May but the balance sheet is built to \"weather a severe storm,\" he says.</li>    <li>The firm reiterated its Equal Weight rating and price target of $33, near a Street low and now implying 4.3% downside.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3422708\" data-linked=\"Micron -4.3% as Morgan Stanley sees no 2019 rebound\" data-tweet=\"$MU - Micron -4.3% as Morgan Stanley sees no 2019 rebound https://seekingalpha.com/news/3422708-micronminus-4_3-morgan-stanley-sees-no-2019-rebound?source=tweet\" data-url=\"https://seekingalpha.com/news/3422708-micronminus-4_3-morgan-stanley-sees-no-2019-rebound\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>63&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422704\" data-ts=\"1547475977\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422704-wedbush-talks-apple-m-targets-and-xr-price-cuts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wedbush talks Apple M&amp;A targets and XR price cuts</a></h4><ul> <li>Wedbush analyst Dan Ives calls Apple's (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) pricing hubris on iPhone XR the major factor in the \"earnings debacle\" for December. Ives say while iPhone XS continues to be focused on premium price points, the linchpin on the upgrade cycle was XR within the China region representing ~20% of all iPhones in the window of an upgrade opportunity. \"To put numbers around this, with ~750 million active iPhones worldwide based on our estimates and 350 million of those in a window of an upgrade opportunity over the next 12 to 18 months, we estimate between 60 million to 70 million of iPhones slated to be upgraded/new purchases are out of the key China region,\" he notes.</li>  <li>Ives thinks Apple should \"aggressively\" cut prices in China on XR and pull forward an estimated is roughly 15M to 20M iPhones sales that would otherwise be sitting idle or be lost to competition.</li><li>He also recommends that Apple make a major content acquisition to drive the services flywheel. \"In a nutshell, ultimately with $250 billion+ of potential dry M&amp;A powder now is the time for Apple to rip off the band-aid and finally do significant content M&amp;A with the landscape ripe otherwise it will be a major strategic mistake in our opinion that will haunt the company for years to come, with content being the rocket fuel in the services engine that is currently missing in the portfolio,\" he writes. On that M&amp;A wildcard, Ives and team call A24, Lionsgate and Sony Pictues (NYSE:<a href='https://seekingalpha.com/symbol/SNE' title='Sony Corporation'>SNE</a>) \"higher probability\" targets and sees Viacom (NYSE:<a href='https://seekingalpha.com/symbol/VIA' title='Viacom Inc.'>VIA</a>)/CBS (NYSE:<a href='https://seekingalpha.com/symbol/CBS' title='CBS Corporation'>CBS</a>) and MGM Studios as \"medium\" probability targets. Netflix, Disney and various videogame publishers are called \"low\" probability targets.</li> <li>Wedbush keeps an Outperform rating on Apple and price target of $200.</li> <li>AAPL <font color=\"red\">-0.76%</font> premarket to $151.10.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3422704\" data-linked=\"Wedbush talks Apple M&amp;A targets and XR price cuts\" data-tweet=\"$AAPL $AAPL $SNE - Wedbush talks Apple M&amp;A targets and XR price cuts https://seekingalpha.com/news/3422704-wedbush-talks-apple-m-targets-and-xr-price-cuts?source=tweet\" data-url=\"https://seekingalpha.com/news/3422704-wedbush-talks-apple-m-targets-and-xr-price-cuts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>34&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422703\" data-ts=\"1547475963\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MBOT\" target=\"_blank\">MBOT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422703-ygyi-mbot-among-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">YGYI, MBOT among premarket gainers</a></h4><ul><li>Microbot Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/MBOT' title='Microbot Medical Inc'>MBOT</a>) <font color=\"green\">+81%</font> <a href=\"https://seekingalpha.com/news/3422619-microbot-medical-nabs-patent-europe-shares-45-percent-premarket\" target=\"_blank\">nabs patent</a> in Europe.</li><li>Gannett (NYSE:<a href='https://seekingalpha.com/symbol/GCI' title='Gannett Co., Inc.'>GCI</a>) <font color=\"green\">+20%</font> as Digital First Media is <a href=\"https://seekingalpha.com/news/3422566-digital-first-media-expected-make-bid-gannett\" target=\"_blank\">expected</a> to make bid.</li><li>Youngevity (NASDAQ:<a href='https://seekingalpha.com/symbol/YGYI' title='Youngevity International, Inc.'>YGYI</a>) <font color=\"green\">+15%</font> on <a href=\"https://seekingalpha.com/pr/17378818-ygyi-announces-exclusive-cross-marketing-agreement-icelandic-glacial-joint-development-new\" target=\"_blank\">adding</a> Icelandic Glacial exclusive cross-marketing agreement.</li><li>PEDEVCO (NYSEMKT:<a href='https://seekingalpha.com/symbol/PED' title='PEDEVCO Corp.'>PED</a>) <font color=\"green\">+14%</font> on <a href=\"https://seekingalpha.com/pr/17379035-pacific-energy-development-enters-agreement-acquire-22000-acres-permian-basin-raises-15\" target=\"_blank\">agreement</a> to acquire 22,000 acres in Permian Basin and raises $15 Million.</li><li>YETI Holdings (NYSE:<a href='https://seekingalpha.com/symbol/YETI' title='Yeti Holdings'>YETI</a>) <font color=\"green\">+11%</font> on positive <a href=\"https://seekingalpha.com/news/3422676-baml-expects-yeti-momentum-continue\" target=\"_blank\">update</a>.</li><li>Boot Barn Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/BOOT' title='Boot Barn Holdings'>BOOT</a>) <font color=\"green\">+10%</font> <a href=\"https://seekingalpha.com/news/3422643-boot-barn-plus-8-percent-strong-holiday-sales\" target=\"_blank\">after</a> strong holiday sales.</li><li>Goldcorp (NYSE:<a href='https://seekingalpha.com/symbol/GG' title='Goldcorp Inc.'>GG</a>) <font color=\"green\">+9%</font> as Newmont Mining <a href=\"https://seekingalpha.com/news/3422587-newmont-mining-goldcorp-combine-10b-stock-deal\" target=\"_blank\">buy shares</a> of the company.</li><li>Midstates Petroleum (NYSE:<a href='https://seekingalpha.com/symbol/MPO' title='Midstates Petroleum'>MPO</a>) <font color=\"green\">+8%</font> to <a href=\"https://seekingalpha.com/news/3422637-midstates-petroleum-buy-back-5m-shares-10\" target=\"_blank\">buy back</a> 5M shares at $10 each.</li><li>Companhia de Saneamento Basico do Estado de Sao Paulo - SABESP (NYSE:<a href='https://seekingalpha.com/symbol/SBS' title='Companhia de Saneamento Basico do Estado de Sao Paulo-SABESP'>SBS</a>) <font color=\"green\">+8%</font>.</li><li>LiqTech International (NYSEMKT:<a href='https://seekingalpha.com/symbol/LIQT' title='LiqTech International, Inc.'>LIQT</a>) <font color=\"green\">+8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3422703\" data-linked=\"YGYI, MBOT among premarket gainers\" data-tweet=\"$MBOT $MBOT $GCI - YGYI, MBOT among premarket gainers https://seekingalpha.com/news/3422703-ygyi-mbot-among-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3422703-ygyi-mbot-among-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422699\" data-ts=\"1547475741\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GS\" target=\"_blank\">GS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422699-bank-investors-mull-citis-lame-ficc-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bank investors mull Citi&#39;s lame FICC results</a></h4><ul><li>Wait, we thought high volatility was supposed to be a boon for trading revenue (and profits) at the big Wall Street banks?</li><li>Well, it didn't help at Citigroup, <a href=\"https://seekingalpha.com/news/3422678-citi-ficc-results-suggest-volatility-boon-q4\" target=\"_blank\">which just reported a</a> 39% plunge in Q/Q revenue for fixed-income trading. That led to an overall revenue miss for the fourth quarter.</li><li>Citi's <font color=\"red\">down 1.3%</font> premarket. Peers Goldman Sachs (NYSE:<a href='https://seekingalpha.com/symbol/GS' title='Goldman Sachs Group Inc.'>GS</a>), Morgan Stanley (NYSE:<a href='https://seekingalpha.com/symbol/MS' title='Morgan Stanley'>MS</a>), Bank of America (NYSE:<a href='https://seekingalpha.com/symbol/BAC' title='Bank of America Corporation'>BAC</a>), and JPMorgan (NYSE:<a href='https://seekingalpha.com/symbol/JPM' title='JPMorgan Chase & Co.'>JPM</a>) are <font color=\"red\">down about 1%</font> or more. Wells Fargo (NYSE:<a href='https://seekingalpha.com/symbol/WFC' title='Wells Fargo & Co.'>WFC</a>) is <font color=\"red\">lower by 0.55%</font>.</li><li>The Financial SPDR (NYSEARCA:<a href='https://seekingalpha.com/symbol/XLF' title='Financial Select Sector SPDR ETF'>XLF</a>) is <font color=\"red\">down 1%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3422699\" data-linked=\"Bank investors mull Citi&#39;s lame FICC results\" data-tweet=\"$GS $GS $MS - Bank investors mull Citi&#39;s lame FICC results https://seekingalpha.com/news/3422699-bank-investors-mull-citis-lame-ficc-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3422699-bank-investors-mull-citis-lame-ficc-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422698\" data-ts=\"1547475713\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABT\" target=\"_blank\">ABT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422698-fda-oks-abbott-device-for-heart-defect-in-preemies-and-newborns\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Abbott device for heart defect in preemies and newborns</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/17378994-fda-approves-worlds-first-device-treatment-premature-babies-newborns-opening-hearts-common\" target=\"_blank\">approves </a>Abbott's (NYSE:<a href='https://seekingalpha.com/symbol/ABT' title='Abbott Laboratories'>ABT</a>) Amplatzer Piccolo Occluder, a small pea-sized device, for the treatment of premature babies and newborns with ductus arteriosus, an opening between two blood vessels leading from the heart.</li><li>The product is a self-expanding wire mesh, inserted through a small incision in the leg and guided through vessels to the heart, that seals the opening.</li><li>Shares are down <font color=\"red\">1%</font> premarket, albeit on only 448 shares.</li></ul><div class=\"tiny-share-widget\" data-id=\"3422698\" data-linked=\"FDA OKs Abbott device for heart defect in preemies and newborns\" data-tweet=\"$ABT - FDA OKs Abbott device for heart defect in preemies and newborns https://seekingalpha.com/news/3422698-fda-oks-abbott-device-for-heart-defect-in-preemies-and-newborns?source=tweet\" data-url=\"https://seekingalpha.com/news/3422698-fda-oks-abbott-device-for-heart-defect-in-preemies-and-newborns\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422697\" data-ts=\"1547475412\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PCG\" target=\"_blank\">PCG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422697-pcg-nem-and-tlrd-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PCG, NEM and TLRD among premarket losers</a></h4><ul><li>PG&amp;E (NYSE:<a href='https://seekingalpha.com/symbol/PCG' title='PG&E Corporation'>PCG</a>) <font color=\"red\">-49% </font>as it prepares to <a href=\"https://seekingalpha.com/news/3422615-pg-and-e-file-chapter-11-bankruptcy\" target=\"_blank\">file</a> for Chapter 11 bankruptcy.</li><li>Tailored Brands (NYSE:<a href='https://seekingalpha.com/symbol/TLRD' title='Tailored Brands, Inc'>TLRD</a>) <font color=\"red\">-15%</font> on <a href=\"https://seekingalpha.com/pr/17378488-tailored-brands-inc-updates-outlook-advance-icr-conference\" target=\"_blank\">updating</a> 2018 outlook.</li><li>Ascena Retail Group (NASDAQ:<a href='https://seekingalpha.com/symbol/ASNA' title='Ascena Retail Group Inc'>ASNA</a>) <font color=\"red\">-14%</font> on <a href=\"https://seekingalpha.com/pr/17378751-ascena-retail-group-inc-announces-holiday-sales-results-updates-second-quarter-earnings-per\" target=\"_blank\">announcing</a> holiday sales and Q2 2019 guidance.</li><li>AXTI (NASDAQ:<a href='https://seekingalpha.com/symbol/AXTI' title='AXT Inc'>AXTI</a>) <font color=\"red\">-8%</font> on <a href=\"https://seekingalpha.com/pr/17378501-axt-inc-updates-expectations-fourth-quarter-2018\" target=\"_blank\">announcing</a> Q4 2018 revenue guidance.</li><li>ToughBuilt Industries (NASDAQ:<a href='https://seekingalpha.com/symbol/TBLT' title='ToughBuilt Industries, Inc.'>TBLT</a>) <font color=\"red\">-8%</font>.</li><li>SAExploration Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/SAEX' title='SAExploration Holdings, Inc.'>SAEX</a>) <font color=\"red\">-8%</font>.</li><li>Camber Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/CEI' title='Camber Energy, Inc.'>CEI</a>) <font color=\"red\">-8%</font>.</li><li>Newmont Mining (NYSE:<a href='https://seekingalpha.com/symbol/NEM' title='Newmont Mining Corporation &#40;Holding Company&#41;'>NEM</a>) <font color=\"red\">-7% </font>on <a href=\"https://seekingalpha.com/news/3422587-newmont-mining-goldcorp-combine-10b-stock-deal\" target=\"_blank\">combining</a> with GoldCorp.</li><li>Autohome (NYSE:<a href='https://seekingalpha.com/symbol/ATHM' title='Autohome Inc.'>ATHM</a>) <font color=\"red\">-7%</font>.</li><li>Western Digital (NYSE:<a href='https://seekingalpha.com/symbol/WDC' title='Western Digital Corporation'>WDC</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3422697\" data-linked=\"PCG, NEM and TLRD among premarket losers\" data-tweet=\"$PCG $PCG $TLRD - PCG, NEM and TLRD among premarket losers https://seekingalpha.com/news/3422697-pcg-nem-and-tlrd-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3422697-pcg-nem-and-tlrd-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:16 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422696\" data-ts=\"1547475371\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MAXR\" target=\"_blank\">MAXR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422696-maxarplus-2_4-names-jablonsky-new-ceo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Maxar +2.4% as it names Jablonsky new CEO</a></h4><ul>   <li>Maxar Technologies (NYSE:<a href='https://seekingalpha.com/symbol/MAXR' title='Maxar Technologies Inc'>MAXR</a>) is <font color=\"green\">up 2.4%</font> premarket following announcement of a <a href=\"https://seekingalpha.com/pr/17378626-maxar-technologies-announces-ceo-transition\" target=\"_blank\">CEO transition</a>.</li>    <li>Daniel Jablonsky has been named president and CEO, effective immediately.</li>    <li>He succeeds Howard Lance, who's resigned those two roles and from the board. Jablonsky will take a board seat as well.</li>    <li>Jablonsky most recently was president of Maxar's DigitalGlobe and is a former general counsel and general manager of the U.S. and International Defense and Intelligence businesses.</li>    <li>Maxar's market cap has been cut in half in the week since the <a href=\"https://seekingalpha.com/news/3420949-maxar-minus-5-percent-satellite-failure\" target=\"_blank\">failure/assumed loss</a> of its WorldView-4 satellite.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3422696\" data-linked=\"Maxar +2.4% as it names Jablonsky new CEO\" data-tweet=\"$MAXR - Maxar +2.4% as it names Jablonsky new CEO https://seekingalpha.com/news/3422696-maxarplus-2_4-names-jablonsky-new-ceo?source=tweet\" data-url=\"https://seekingalpha.com/news/3422696-maxarplus-2_4-names-jablonsky-new-ceo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422695\" data-ts=\"1547475090\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LULU\" target=\"_blank\">LULU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422695-lululemonplus-3-after-holiday-sales-dazzle\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lululemon +3% after holiday sales dazzle</a></h4><ul> <li>Lululemon (NASDAQ:<a href='https://seekingalpha.com/symbol/LULU' title='Lululemon Athletica Inc.'>LULU</a>) <font color=\"green\">jumps 3.3%</font> in premarket trading to $136.50 after delivering a strong holiday sales update.</li> <li>MKM Partners says Lululemon's mid-to-high teens Q4 comparable sales growth was likely driven by new customer acceleration and strong product acceptance. That development bodes well for 2019 as a whole as the brand's strength generates sales instead of promotions.</li><li>The retailer guided its forecast for total revenue for the crucial holiday quarter to $1.14B to $1.15B vs. $1.12B consensus.</li> <li>Shares of LULU were already up 11% over the last four weeks in anticipation of a strong holiday print. LULU hasn't traded over $150 since October.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3422606-lululemon-athletica-updates-q4-guidance-ahead-icr-conference\" target=\"_blank\">Lululemon Athletica updates Q4 guidance ahead of the ICR conference</a> (Jan. 14)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3422695\" data-linked=\"Lululemon +3% after holiday sales dazzle\" data-tweet=\"$LULU - Lululemon +3% after holiday sales dazzle https://seekingalpha.com/news/3422695-lululemonplus-3-after-holiday-sales-dazzle?source=tweet\" data-url=\"https://seekingalpha.com/news/3422695-lululemonplus-3-after-holiday-sales-dazzle\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422693\" data-ts=\"1547475052\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RDC\" target=\"_blank\">RDC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422693-rowan-receives-new-exchange-rate-proposal-from-ensco\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rowan receives new exchange rate proposal from Ensco</a></h4><ul><li>Rowan Cos. (NYSE:<a href='https://seekingalpha.com/symbol/RDC' title='Rowan Companies plc'>RDC</a>) says Ensco (NYSE:<a href='https://seekingalpha.com/symbol/ESV' title='Ensco PLC'>ESV</a>) has made a proposal to <a href=\"https://www.streetinsider.com/Corporate+News/Rowan+Cos.+%28RDC%29+Confirms+Receipt+of+Exchange+Rate+Proposal+from+Ensco+%28ESV%29/15003043.html\" target=\"_blank\">increase the exchange ratio</a> for its all-stock merger; RDC <font color=\"green\">+4.9%</font>, ESV <font color=\"red\">-5.3%</font> pre-market.</li><li>RDC shareholders would receive 2.6 ESV shares for each RDC share, a 17.4% increase from the exchange ratio of 2.215 in the original agreement <a href=\"https://seekingalpha.com/news/3395654-offshore-drillers-ensco-rowan-merge-stock-deal\" target=\"_blank\">outlined in October</a>.</li><li>Based on Friday's closing prices, the new ratio would value RDC shares at $11.34 each, 8.2% above Friday's close but <a href=\"https://www.marketwatch.com/story/ensco-raises-proposed-stock-exchange-ratio-for-buyout-bid-for-rowan-2019-01-14\" target=\"_blank\">39.6% below the implied value</a> of the original deal.</li><li>The planned merger would \"create an industry leader in offshore drilling across all water depths\" and the broadest geographic presence of any offshore driller.</li></ul><div class=\"tiny-share-widget\" data-id=\"3422693\" data-linked=\"Rowan receives new exchange rate proposal from Ensco\" data-tweet=\"$RDC $RDC $VAL - Rowan receives new exchange rate proposal from Ensco https://seekingalpha.com/news/3422693-rowan-receives-new-exchange-rate-proposal-from-ensco?source=tweet\" data-url=\"https://seekingalpha.com/news/3422693-rowan-receives-new-exchange-rate-proposal-from-ensco\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>45&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422692\" data-ts=\"1547475034\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRAY\" target=\"_blank\">CRAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422692-cray-sees-2018-top-line-in-line-consensus-shares-down-4-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cray sees 2018 top line in line with consensus; shares down 4% premarket</a></h4><ul><li>Cray (NASDAQ:<a href='https://seekingalpha.com/symbol/CRAY' title='Cray Inc'>CRAY</a>) is down <font color=\"red\">4%</font> premarket, albeit on only 100 shares, following its <a href=\"https://seekingalpha.com/pr/17378845-cray-announces-selected-preliminary-2018-financial-results\" target=\"_blank\">release </a>of preliminary 2018 results. Revenues should be ~$450M, in line with consensus. Quick assets at year-end were a bit above $240M.</li><li>Revenue this quarter should be ~$70M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3422692\" data-linked=\"Cray sees 2018 top line in line with consensus; shares down 4% premarket\" data-tweet=\"$CRAY - Cray sees 2018 top line in line with consensus; shares down 4% premarket https://seekingalpha.com/news/3422692-cray-sees-2018-top-line-in-line-consensus-shares-down-4-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3422692-cray-sees-2018-top-line-in-line-consensus-shares-down-4-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:10 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422690\" data-ts=\"1547474641\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DOMO\" target=\"_blank\">DOMO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422690-evercore-softens-view-on-western-digital-in-premarket-analyst-action\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Evercore softens view on Western Digital in premarket analyst action</a></h4><ul><li>Domo (NASDAQ:<a href='https://seekingalpha.com/symbol/DOMO' title='Domo, Inc.'>DOMO</a>) initiated with Buy rating and $27 (19% upside) price target at Needham.</li><li>IQIYI (NASDAQ:<a href='https://seekingalpha.com/symbol/IQ' title='iQIYI, Inc'>IQ</a>) initiated with Underperform rating and $11 (38% downside risk) price target at Bernstein.</li><li>Netease (NASDAQ:<a href='https://seekingalpha.com/symbol/NTES' title='NetEase, Inc'>NTES</a>) upgraded to Overweight with a $300 (23% upside) price target at Barclays. Shares up a fraction premarket.</li><li>Infosys (NASDAQ:<a href='https://seekingalpha.com/symbol/INFY' title='Infosys Limited, Inc.'>INFY</a>) upgraded to Neutral at Nomura. Shares down <font color=\"red\">3%</font> premarket.</li><li>Crown Castle (NYSE:<a href='https://seekingalpha.com/symbol/CCI' title='Crown Castle International Corp.'>CCI</a>) downgraded to Neutral with a $110 (2% upside) price target at Goldman Sachs. Shares down <font color=\"red\">1% </font>premarket.</li><li>Teradyne (NYSE:<a href='https://seekingalpha.com/symbol/TER' title='Teradyne Inc.'>TER</a>) downgraded to Neutral at Evercore ISI.</li><li>Western Digital (NYSE:<a href='https://seekingalpha.com/symbol/WDC' title='Western Digital Corporation'>WDC</a>) <a href=\"https://www.cnbc.com/2019/01/14/chipmaker-western-digital-falls-after-evercore-isi-downgrade.html\" target=\"_blank\">downgraded </a>to Underperform at Evercore citing competitive pressures that could put its dividend at risk. Shares down <font color=\"red\">5%</font> premarket.</li><li>Vocera Communications (NYSE:<a href='https://seekingalpha.com/symbol/VCRA' title='Vocera Communications'>VCRA</a>) downgraded to Neutral at Dougherty &amp; Co. Shares down <font color=\"red\">2%</font> premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3422690\" data-linked=\"Evercore softens view on Western Digital in premarket analyst action\" data-tweet=\"$DOMO $DOMO $IQ - Evercore softens view on Western Digital in premarket analyst action https://seekingalpha.com/news/3422690-evercore-softens-view-on-western-digital-in-premarket-analyst-action?source=tweet\" data-url=\"https://seekingalpha.com/news/3422690-evercore-softens-view-on-western-digital-in-premarket-analyst-action\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422676\" data-ts=\"1547473246\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/YETI\" target=\"_blank\">YETI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422676-baml-expects-yeti-momentum-to-continue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BAML expects Yeti momentum to continue</a></h4><ul> <li>Bank of America Merrill Lynch doubles down on its bullish view on Yeti Holdings (NYSE:<a href='https://seekingalpha.com/symbol/YETI' title='Yeti Holdings'>YETI</a>) after the consumer products seller guided for <a href=\"https://seekingalpha.com/pr/17378111-yeti-announces-preliminary-fourth-quarter-fiscal-year-2018-net-sales-results-updated-fiscal\" target=\"_blank\">Q4</a> revenue growth of 19% off 45% growth in the direct-to-consumer channel and 24% growth in the drinkware category.</li> <li>The firm expects the strong brand momentum displayed during the holiday period to roll into 2019 and beyond.</li> <li>\"We believe YETI\u2019s long-term growth algorithm of +10-15% revenue growth, gross margin between 50-52%, and adjusted EBITDA margin between 19-22% remains ontrack,\" advises BAML.</li> <li>BAML's price objective on Yeti is $22.</li> <li>Shares of Yeti are <font color=\"green\">up 7.96%</font> premarket to $18.05.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3422676\" data-linked=\"BAML expects Yeti momentum to continue\" data-tweet=\"$YETI - BAML expects Yeti momentum to continue https://seekingalpha.com/news/3422676-baml-expects-yeti-momentum-to-continue?source=tweet\" data-url=\"https://seekingalpha.com/news/3422676-baml-expects-yeti-momentum-to-continue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:40 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422675\" data-ts=\"1547472970\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNAP\" target=\"_blank\">SNAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422675-citi-upgrades-snap-on-ad-revenue-optimism\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Citi upgrades Snap on ad revenue optimism</a></h4><ul><li>Snap (NYSE:<a href='https://seekingalpha.com/symbol/SNAP' title='Snap Inc.'>SNAP</a>) <font color=\"green\">+2.7%</font> premarket after Citi analyst Mark May <a href=\"https://www.cnbc.com/2019/01/14/snap-shares-rally-after-citi-upgrades-stock-sees-better-ad-revenues.html?__source=twitter%7Ctech\" target=\"_blank\">raised</a> his rating on shares to Neutral from Sell, and upped his PT to $7 from $6.</li><li>A growing number of advertisers are optimistic in the company's ability to showcase media, and there are better profit expectations surrounding its upcoming Android app launch.</li><li>\"Advertising average revenue per user accelerated in the third quarter (both in the U.S. and Internationally), which bodes well,\" he added.</li><li>SNAP is <font color=\"red\">down more than 70%</font> since May downgraded the stock last February amid competition from Facebook-owned Instagram.</li></ul><div class=\"tiny-share-widget\" data-id=\"3422675\" data-linked=\"Citi upgrades Snap on ad revenue optimism\" data-tweet=\"$SNAP - Citi upgrades Snap on ad revenue optimism https://seekingalpha.com/news/3422675-citi-upgrades-snap-on-ad-revenue-optimism?source=tweet\" data-url=\"https://seekingalpha.com/news/3422675-citi-upgrades-snap-on-ad-revenue-optimism\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422673\" data-ts=\"1547472763\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IGXT\" target=\"_blank\">IGXT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422673-intelgenx-and-tilray-on-go-q4-launch-of-cannabis-infused-oral-film\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">IntelGenx and Tilray on go with Q4 launch of cannabis-infused oral film</a></h4><ul><li>IntelGenx (<a href='https://seekingalpha.com/symbol/IGXT' title='IntelGenx Technologies Corp.'>OTCQX:IGXT</a>) <a href=\"https://seekingalpha.com/pr/17378757-intelgenx-provides-update-cannabis-infused-versafilm-program-following-recently-proposed\" target=\"_blank\">announces </a>that it and development partner Tilray (NASDAQ:<a href='https://seekingalpha.com/symbol/TLRY' title='Tilray, Inc.'>TLRY</a>) should be ready to launch a cannabis-infused VersaFilm product in Canada in late Q4, shortly after new regulations go into effect allowing adults to purchase edible cannabis products. The companies have been collaborating since November 2018.</li><li>TLRY is off <font color=\"red\">2%</font> premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3422673\" data-linked=\"IntelGenx and Tilray on go with Q4 launch of cannabis-infused oral film\" data-tweet=\"$IGXT $IGXT $TLRY - IntelGenx and Tilray on go with Q4 launch of cannabis-infused oral film https://seekingalpha.com/news/3422673-intelgenx-and-tilray-on-go-q4-launch-of-cannabis-infused-oral-film?source=tweet\" data-url=\"https://seekingalpha.com/news/3422673-intelgenx-and-tilray-on-go-q4-launch-of-cannabis-infused-oral-film\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422667\" data-ts=\"1547472445\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OMER\" target=\"_blank\">OMER</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422667-omeros-sees-q4-2018-revenue-high-22m-shares-up-4-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Omeros sees Q4 2018 revenue as high as $22M; shares up 4% premarket</a></h4><ul> <li>Omeros Corporation (NASDAQ:<a href='https://seekingalpha.com/symbol/OMER' title='Omeros Corporation'>OMER</a>) <a href=\"https://seekingalpha.com/pr/17378613-omeros-corporation-announces-record-high-quarterly-revenue-results-fourth-quarter-2018\" target=\"_blank\">announces</a> preliminary Q4 2018 revenue.</li><li>Total and OMIDRIA revenues         for Q4 2018 are expected to be ~$22M compared to $4.6M and         $13.8M in 3Q 2018 and Q4 2017, respectively.</li><li>Annualized run rate of weekly net sales in December was ~$100M.</li>     <li>The company       expects to release complete Q4 and FY 2018 results by March 1.</li><li>Shares are up <font color=\"green\">4%</font> premarket.</li>     </ul><div class=\"tiny-share-widget\" data-id=\"3422667\" data-linked=\"Omeros sees Q4 2018 revenue as high as $22M; shares up 4% premarket\" data-tweet=\"$OMER - Omeros sees Q4 2018 revenue as high as $22M; shares up 4% premarket https://seekingalpha.com/news/3422667-omeros-sees-q4-2018-revenue-high-22m-shares-up-4-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3422667-omeros-sees-q4-2018-revenue-high-22m-shares-up-4-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422663\" data-ts=\"1547472078\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SRNE\" target=\"_blank\">SRNE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422663-scilexs-ztlido-added-to-express-scripts-national-formularies\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Scilex&#39;s ZTlido added to Express Scripts national formularies</a></h4><ul> <li>Scilex Pharmaceuticals, a subsidiary of Sorrento Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SRNE' title='Sorrento Therapeutics, Inc.'>SRNE</a>), <a href=\"https://seekingalpha.com/pr/17378578-scilex-announces-addition-ztlido-express-scripts-national-formularies\" target=\"_blank\">announces</a> that Express Scripts (NASDAQ:<a href='https://seekingalpha.com/symbol/ESRX' title='Express Scripts, Inc.'>ESRX</a>) has added ZTlido (lidocaine topical system) 1.8% to its commercial national formularies.</li><li>ZTLIDO is indicated for relief of pain associated with postherpetic neuralgia &#40;PHN&#41;, also referred to as post-shingles pain.</li><li>SRNE shares are up 3% premarket.</li>     </ul><div class=\"tiny-share-widget\" data-id=\"3422663\" data-linked=\"Scilex&#39;s ZTlido added to Express Scripts national formularies\" data-tweet=\"$SRNE $SRNE $ESRX - Scilex&#39;s ZTlido added to Express Scripts national formularies https://seekingalpha.com/news/3422663-scilexs-ztlido-added-to-express-scripts-national-formularies?source=tweet\" data-url=\"https://seekingalpha.com/news/3422663-scilexs-ztlido-added-to-express-scripts-national-formularies\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:21 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422656\" data-ts=\"1547471470\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RWLK\" target=\"_blank\">RWLK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422656-rewalk-down-17-after-preliminary-2018-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ReWalk down 17% after preliminary 2018 revenue</a></h4><ul><li>ReWalk Robotics (NASDAQ:<a href='https://seekingalpha.com/symbol/RWLK' title='ReWalk Robotics'>RWLK</a>) <a href=\"https://seekingalpha.com/pr/17378574-rewalk-announces-preliminary-fiscal-year-2018-revenue\" target=\"_blank\">announces</a> preliminary FY 2018 total revenue of ~$6.5M.</li><li>Shares are down <font color=\"red\">17%</font> premarket.</li>       </ul><div class=\"tiny-share-widget\" data-id=\"3422656\" data-linked=\"ReWalk down 17% after preliminary 2018 revenue\" data-tweet=\"$RWLK - ReWalk down 17% after preliminary 2018 revenue https://seekingalpha.com/news/3422656-rewalk-down-17-after-preliminary-2018-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3422656-rewalk-down-17-after-preliminary-2018-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:11 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3422654\" data-ts=\"1547471420\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SJR\" target=\"_blank\">SJR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3422654-shaw-communications-beats-c-0_05-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shaw Communications beats by C$0.05, beats on revenue</a></h4><ul><li>Shaw Communications (NYSE:<a href='https://seekingalpha.com/symbol/SJR' title='Shaw Communications Inc.'>SJR</a>): Q1 GAAP EPS of C$0.36 beats by C$0.05.</li><li>Revenue of C$1.36B (+8.8% Y/Y) <font color=\"green\">beats by C$40M</font>.</li><li>Shares <font color=\"green\">+4.11%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/17378763-shaw-announces-first-quarter-fiscal-2019-results\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3422654\" data-linked=\"Shaw Communications beats by C$0.05, beats on revenue\" data-tweet=\"$SJR - Shaw Communications beats by C$0.05, beats on revenue https://seekingalpha.com/news/3422654-shaw-communications-beats-c-0_05-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3422654-shaw-communications-beats-c-0_05-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:10 AM </div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}